STOCK TITAN

Ardent Health holders offer 8M shares in resale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B5

Rhea-AI Filing Summary

Ardent Health, Inc. (ARDT) is named in a preliminary resale offering in which selling stockholders offer 8,000,000 common shares; underwriters may buy up to 1,200,000 additional shares from them within 30 days. Ardent will receive none of the proceeds from the stockholders’ sales.

Subject to completion of the offering, Ardent intends to repurchase up to 1,500,000 offered shares from the underwriters at the price they pay the selling stockholders, using cash on hand, and then cancel the repurchased shares. The offering is not conditioned on the repurchase. Assuming the full repurchase and no exercise of the underwriters’ option, 139,436,393 shares are expected to be outstanding afterward, compared with 140,936,393 shares outstanding as of November 2, 2026.

After the offering and repurchase, EGI-AM is expected to hold 70,109,780 shares and approximately 50.3% of voting power; it would hold approximately 49.5% if the option is exercised in full. Ardent would remain a controlled company under NYSE rules. Separately, Ardent entered an agreement to acquire Boone Health for $47 million, with closing expected in the first quarter of 2027, subject to customary closing conditions.

Filing Explained

EGI-AM’s board-nomination right depends on at least fifty percent voting power; the full-option scenario projects forty-nine point five percent.

This preliminary prospectus supplement describes a proposed resale by stockholders and an intended company repurchase, neither reported as completed. The repurchase is outside the existing stock-repurchase plan and would not reduce its remaining authorization. At September 30, 2026, that plan had $48 million of authorization remaining.

EGI-AM’s right to nominate a majority of directors is conditioned on holding at least 50% of voting power; its projected holding is 50.3% without the underwriters’ option and 49.5% if the option is fully exercised, below that stated threshold in the latter scenario.

The cover leaves the public offering price and underwriting discount blank; the prospectus supplement states final terms of a specific takedown, so those sale economics are not established in this preliminary document.

Base shares offered by selling stockholders 8,000,000 shares Preliminary resale offering
Underwriters’ additional-share option Up to 1,200,000 shares Additional shares from selling stockholders; exercisable within 30 days of the prospectus supplement date
Concurrent share repurchase Up to 1,500,000 shares Ardent intends to repurchase offered shares from the underwriters, subject to completion of the offering
Shares outstanding after offering and repurchase 139,436,393 shares Assumes Ardent repurchases 1,500,000 shares and the underwriters do not exercise their option
EGI-AM shares after offering and repurchase 70,109,780 shares Assuming the underwriters do not exercise their option
EGI-AM voting power Approximately 50.3% After offering and repurchase; approximately 49.5% if the underwriters exercise their option in full
Boone Health acquisition consideration $47 million Cash consideration under the definitive agreement
Last reported sale price $18.10 per share November 16, 2026
Concurrent Share Repurchase financial
"the “Concurrent Share Repurchase”"
A concurrent share repurchase is when a company buys back its own shares at the same time it conducts another equity-related transaction, such as a new stock issuance or a selling shareholder offering. It matters to investors because the simultaneous buyback can offset dilution, change the number of shares outstanding and ownership percentages, and influence per-share metrics like earnings per share, much like swapping items in and out of a basket to keep the overall quantity or composition steady.
controlled company regulatory
"continue to be a “controlled company” under the rules of the NYSE"
A controlled company is a publicly traded firm where one shareholder or a small group holds enough voting power to determine board members and major strategic choices. For investors this matters because control can speed decision-making and protect long-term plans, but it also raises the risk that majority owners will favor their own interests over minority shareholders, reducing outside oversight—like a family-owned restaurant that sold shares but the family still calls the shots.
underwriters’ option to purchase additional shares financial
"Option to Purchase Additional Shares of Common Stock"
beneficial ownership regulatory
"beneficial ownership of our common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
lock-up agreements financial
"have agreed with the underwriters"
A lock-up agreement is a contract that prevents company insiders—founders, employees, and early investors—from selling their shares for a set period after a public stock offering. It matters to investors because it keeps a large block of shares off the market temporarily; when the lock-up ends, those holders can sell and this increased supply can cause the stock price to fall, similar to a timed release that suddenly opens a valve.
Rule 144 regulatory
"sold pursuant to an exemption from registration such as Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Offering Type secondary
Securities Offered Ardent Health, Inc. common stock offered by selling stockholders
Offering Amount 8,000,000 shares, or 9,200,000 shares if the underwriters’ option is exercised in full
Use of Proceeds Ardent will receive no proceeds from sales by the selling stockholders. Ardent intends to fund a concurrent repurchase of up to 1,500,000 offered shares with cash on hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARDT shares are being sold in the offering?

Selling stockholders are offering 8,000,000 shares, with an underwriters’ option to purchase up to 1,200,000 additional shares within 30 days. The total would be 9,200,000 shares if the option is exercised in full.

Will Ardent Health receive proceeds from the ARDT share offering?

Ardent will receive none of the proceeds from the selling stockholders’ share sales. Separately, subject to completion of the offering, Ardent intends to use cash on hand to repurchase up to 1,500,000 offered shares from the underwriters and cancel them.

How much ARDT stock will EGI-AM own after the offering?

After the offering and concurrent repurchase, EGI-AM is expected to beneficially own 70,109,780 shares, representing approximately 50.3% of voting power, or approximately 49.5% if the underwriters exercise their option in full. EGI-AM retains the right to designate at least six of the 11 directors while it beneficially owns at least 50% of voting power.

What does Ardent Health’s Boone Health acquisition include?

Ardent agreed to pay $47 million for Boone Health, including the 392-bed Boone Hospital Center, Boone Health Medical Group, 19 sites of care, related ancillary services and associated real estate. Closing is expected in the first quarter of 2027, subject to customary closing conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Table of Contents
The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
 Filed Pursuant to Rule 424(b)(5)​
 Registration No. 333-289763​
SUBJECT TO COMPLETION, DATED NOVEMBER 17, 2026
PRELIMINARY PROSPECTUS SUPPLEMENT
To Prospectus dated August 25, 2025
8,000,000 shares
[MISSING IMAGE: lg_ardenthealth-4clr.jpg]
Ardent Health, Inc.
Common stock
​
The selling stockholders identified in this prospectus supplement are offering 8,000,000 shares of common stock of Ardent Health, Inc. We will not receive any of the proceeds of the sale of our common stock being sold in this offering, including any shares that the selling stockholders may sell pursuant to the underwriters’ option to purchase additional shares of our common stock. The underwriters have an option to purchase up to an additional 1,200,000 shares from the selling stockholders on the same terms and conditions noted below within 30 days of the date of this prospectus supplement.
Our common stock is listed on the New York Stock Exchange (the “NYSE”) under the symbol “ARDT.” The last reported sale price per share of our common stock on November 16, 2026 was $18.10 per share.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-6 of this prospectus supplement, as well as the other information included or incorporated or deemed incorporated by reference herein.
Subject to the completion of this offering, we intend to concurrently repurchase from the underwriters up to 1,500,000 of the shares of our common stock that are the subject of this offering at a price per share equal to the price at which the underwriters will purchase the shares from the selling stockholders in this offering (the “Concurrent Share Repurchase”). The underwriters will not receive any compensation for the shares of common stock being repurchased by us. This offering is not conditioned upon the completion of the Concurrent Share Repurchase. See “Prospectus Supplement Summary—Concurrent Share Repurchase” and “The Concurrent Share Repurchase.”
​ ​ ​
Per share
​ ​
Total
​
Public offering price(1) ​ ​ ​ $ ​ ​ ​ ​ $ ​ ​
Underwriting discounts and commissions(2) ​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
Proceeds, before expenses, to the selling stockholders(3) ​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
(1) Total public offering price does not include the shares of common stock sold by the selling stockholders and repurchased by us from the underwriters in the Concurrent Share Repurchase, for which no underwriting discounts or commissions were paid.
(2) See “Underwriting” for a description of the compensation payable to the underwriters.
(3) Includes the shares of common stock sold by the selling stockholders and repurchased by us from the underwriters in the Concurrent Share Repurchase for which no underwriting discounts or commissions were paid.
Neither the U.S. Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares to purchasers on or about            , 2026.
​
​ J.P. Morgan ​ ​
Barclays
​
​
BofA Securities
​ ​ Citigroup ​ ​
Leerink Partners
​ ​
Mizuho
​
​
RBC Capital Markets
​ ​
Stephens Inc.
​ ​
Truist Securities
​
​ ​ ​ ​
Capital One Securities
​ ​ ​ ​
The date of this prospectus supplement is            , 2026.

Table of Contents​​
 
TABLE OF CONTENTS
Prospectus supplement
​ ​ ​
Page
​
ABOUT THIS PROSPECTUS SUPPLEMENT
​ ​ ​ ​ S-iii ​ ​
CAUTIONARY LANGUAGE REGARDING FORWARD-LOOKING STATEMENTS
​ ​ ​ ​ S-iv ​ ​
PROSPECTUS SUPPLEMENT SUMMARY
​ ​ ​ ​ S-1 ​ ​
RISK FACTORS
​ ​ ​ ​ S-6 ​ ​
THE CONCURRENT SHARE REPURCHASE
​ ​ ​ ​ S-10 ​ ​
USE OF PROCEEDS
​ ​ ​ ​ S-11 ​ ​
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS
​ ​ ​ ​ S-12 ​ ​
SELLING STOCKHOLDERS
​ ​ ​ ​ S-15 ​ ​
UNDERWRITING ​ ​ ​ ​ S-16 ​ ​
LEGAL MATTERS
​ ​ ​ ​ S-29 ​ ​
EXPERTS ​ ​ ​ ​ S-30 ​ ​
WHERE YOU CAN FIND MORE INFORMATION
​ ​ ​ ​ S-31 ​ ​
INCORPORATION BY REFERENCE
​ ​ ​ ​ S-32 ​ ​
Prospectus
​ ​ ​
Page
​
ABOUT THIS PROSPECTUS
​ ​ ​ ​ ii ​ ​
SUMMARY ​ ​ ​ ​ 1 ​ ​
RISK FACTORS
​ ​ ​ ​ 2 ​ ​
FORWARD-LOOKING STATEMENTS
​ ​ ​ ​ 3 ​ ​
WHERE YOU CAN FIND MORE INFORMATION
​ ​ ​ ​ 5 ​ ​
INFORMATION INCORPORATED BY REFERENCE
​ ​ ​ ​ 6 ​ ​
USE OF PROCEEDS
​ ​ ​ ​ 7 ​ ​
GENERAL DESCRIPTION OF SECURITIES
​ ​ ​ ​ 8 ​ ​
DESCRIPTION OF CAPITAL STOCK
​ ​ ​ ​ 9 ​ ​
DESCRIPTION OF DEBT SECURITIES
​ ​ ​ ​ 14 ​ ​
SELLING STOCKHOLDERS
​ ​ ​ ​ 26 ​ ​
PLAN OF DISTRIBUTION
​ ​ ​ ​ 28 ​ ​
LEGAL MATTERS
​ ​ ​ ​ 33 ​ ​
EXPERTS ​ ​ ​ ​ 33 ​ ​
​
Neither we, the selling stockholders, nor the underwriters have authorized anyone to provide you with different information or to make any representations other than those contained or incorporated by reference into this prospectus supplement, the accompanying prospectus or in any applicable free writing prospectuses we have prepared. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus supplement, the accompanying prospectus and any applicable free writing prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement, the accompanying prospectus and any applicable free writing prospectus in any jurisdiction in which it is unlawful to make such offer or solicitation. You should assume that the information contained in this prospectus supplement, the accompanying prospectus, any applicable free writing
 
S-i

Table of Contents
 
prospectus and the documents incorporated by reference herein and therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and prospects may have changed since the date such information was presented.
For investors outside the United States: neither we, the selling stockholders, nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus supplement, the accompanying prospectus or any free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus supplement, the accompanying prospectus and any free writing prospectus outside of the United States.
 
S-ii

Table of Contents​
 
ABOUT THIS PROSPECTUS SUPPLEMENT
Unless the context otherwise requires, references in this prospectus supplement to “Ardent,” “the Company,” “we,” “us” and “our” refer to Ardent Health, Inc. and direct and indirect subsidiaries of Ardent Health, Inc. and partnerships and joint ventures in which such subsidiaries are equity owners on a consolidated basis.
This document has two parts, a prospectus supplement and an accompanying prospectus dated August 25, 2025. This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the SEC utilizing a “shelf” registration process. Under this shelf registration process, the selling stockholders may, from time to time, offer and sell our common stock in one or more offerings or resales.
The accompanying prospectus provides you with a general description of our common stock, which the selling stockholders are offering pursuant to this prospectus supplement. This prospectus supplement, which describes certain matters relating to us and the specific terms of this offering of shares of our common stock, adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. Any statement that we make in the accompanying prospectus will be deemed modified or superseded by any inconsistent statement made by us in this prospectus supplement.
The rules of the SEC allow us to incorporate by reference information into this prospectus supplement. This information incorporated by reference is considered to be a part of this prospectus supplement, and information that we file later with the SEC, to the extent incorporated by reference, will automatically update and supersede this information. See “Incorporation by Reference.” You should read both this prospectus supplement and the accompanying prospectus together with the additional information incorporated by reference herein and therein, including all documents described under the headings “Incorporation by Reference” and “Where You Can Find More Information” in this prospectus supplement before investing in our common stock.
 
S-iii

Table of Contents​
 
CAUTIONARY LANGUAGE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein may contain certain “forward-looking statements,” as that term is defined in the U.S. federal securities laws. These forward-looking statements include, but are not limited to, statements other than statements of historical facts, including, among others, statements relating to our future financial performance, our business prospects and strategy, anticipated financial position, liquidity and capital needs, the industry in which we operate and other similar matters. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often identify forward-looking statements. When reviewing the discussion below, you should keep in mind the risks and uncertainties that could impact our business. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risk factors and other cautionary statements described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”), which is incorporated by reference herein. These risks and uncertainties could cause actual results to differ materially from those projected in forward-looking statements contained or incorporated by reference in this prospectus supplement and the accompanying prospectus or implied by past results and trends. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.
Factors, risks, and uncertainties that could cause actual outcomes and results to be materially different from those contemplated include, among others: (1) general economic and business conditions, both nationally and in the regions in which we operate, including the impact of challenging macroeconomic conditions and inflationary pressures, current geopolitical instability, and impacts from the imposition of, or changes in, tariffs, as well as the potential impact on us of uncertain political, financial, credit and capital conditions; (2) possible reductions or other changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs or state directed payments, that could have an adverse effect on our revenues and business; (3) reduction in the reimbursement rates paid by commercial payors, increased reimbursement denials or payment delays by commercial payors, our inability to retain and negotiate favorable contracts with private third party payors, or an increasing volume of uninsured or underinsured patients; (4) effects of changes in healthcare policy or legislation, including the One Big Beautiful Bill Act (the “OBBBA”) and any other reforms that have or may be undertaken by the current presidential administration, and legal and regulatory restrictions on our hospitals that have physician owners; (5) the ability to achieve operating and financial targets, develop and execute mitigation plans to offset to the extent possible impacts from the OBBBA, the expiration of temporary enhanced subsidies for individuals eligible to purchase insurance coverage through health insurance marketplaces and imposition of tariffs, attain expected levels of patient volumes and revenues, and control the costs of providing services; (6) security threats, catastrophic events and other disruptions affecting our, our service providers’ or our joint venture (“JV”) partners’ information technology and related systems, which have adversely affected, and could in the future adversely affect, our relationships with patients and business partners and subject us to legal claims and liabilities, reputational harm and business disruption and adversely affect our financial condition; (7) the highly competitive nature of the healthcare industry and continued industry trends towards clinical transparency and value-based purchasing may impact our competitive position; (8) inability to recruit and retain quality physicians and increased labor costs resulting from increased competition for staffing or a continued or increased shortage of experienced nurses, as well as the loss of key personnel, including key members of our management team; (9) changes to physician utilization practices and treatment methodologies and other factors outside our control that impact demand for medical services and may reduce our revenues and ability to grow profitability; (10) continued industry trends toward value-based purchasing, third party payor consolidation and care coordination among healthcare providers; (11) inability to successfully complete acquisitions, divestitures or strategic JVs or inability to realize all of the anticipated benefits; (12) liabilities because of professional liability and other claims brought against our hospitals, physician practices, outpatient facilities or other business operations; (13) exposure to certain risks and uncertainties by the JVs through which
 
S-iv

Table of Contents
 
we conduct a significant portion of our operations, including anticipated synergies of past acquisitions and the risk that transactions may not receive necessary government clearances; (14) failure to obtain drugs and medical supplies at favorable prices or sufficient volumes; (15) operational, legal and financial risks associated with outsourcing functions to third parties; (16) our facilities are heavily concentrated in Texas and Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states; (17) negative impact of severe weather, climate change, and other factors beyond our control, which could restrict patient access to care or cause one or more facilities to close temporarily or permanently; (18) risks related to the master lease agreement with Ventas, Inc. and its restrictions and limitations on our business; (19) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms; (20) our failure to comply with complex laws and regulations applicable to the healthcare industry or to adjust our operations in response to changing laws and regulations; (21) the impact of governmental claims or governmental investigations, payor audits and litigation brought against our hospitals, physician practices, outpatient facilities or other business operations; (22) actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements; (23) the impact of a deterioration of public health conditions associated with a future pandemic, epidemic or outbreak of infectious disease; (24) inability to or delay in building, acquiring, selling, renovating or expanding our healthcare facilities; (25) failure to comply with federal and state laws relating to Medicare and Medicaid enrollment, permit, licensing and accreditation requirements; (26) the results of our efforts to use technology, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience; (27) our status as a controlled company; (28) conflicts of interest between our controlling stockholder and other holders of our common stock; and (29) other risk factors described in our filings with the SEC, including those discussed in the Annual Report, this prospectus supplement or any free writing prospectus.
We caution you that the foregoing list may not contain all of the risks and uncertainties that may affect the forward-looking statements made in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. You should not rely upon forward-looking statements as predictions of future events.
The forward-looking statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein are based on management’s current beliefs, expectations, and projections about future events and trends affecting our business, results of operations, financial condition, and prospects. These statements are subject to risks, uncertainties, and other factors described in the “Risk Factors” section of the Annual Report. We operate in a competitive and rapidly changing environment where new risks and uncertainties can emerge, making it impossible to predict all potential impacts on our forward-looking statements. Consequently, actual results may differ materially from those described. The forward-looking statements pertain only to the date they are made, and we do not undertake any obligation to update them to reflect new information or events, unless required by law. You are advised not to place undue reliance on these statements and to consult any additional disclosures we may provide through the documents incorporated by reference into this prospectus supplement, the accompanying prospectus, any free writing prospectus and our other filings with the SEC, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
 
S-v

Table of Contents​
 
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights important features of this offering and the information included or incorporated by reference in this prospectus supplement and the accompanying prospectus. Because this is only a summary, it does not contain all of the information you should consider before investing in our common stock. You should carefully read the entire prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, including the sections entitled “Risk Factors” included and incorporated by reference in this prospectus supplement and the accompanying prospectus and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements, related financial statement schedules and the related notes in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, each of which is incorporated by reference herein, before you decide to invest in shares of our common stock.
Our company
We are a leading provider of healthcare services in the United States, operating in eight growing mid-sized urban markets across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas. As of September 30, 2026, we deliver care through a system of 30 acute care hospitals and more than 280 sites of care with over 2,000 employed and affiliated providers. Affiliated providers are physicians and advanced practice providers with whom we contract for services through a professional services agreement or other independent contractor agreement. We hold a leading position in a majority of our markets, and we believe we are one of the leading healthcare systems based on market share and our integrated network of hospitals, ambulatory facilities, and physician practices. We operate either independently or in partnership with premier academic medical centers, large not-for-profit hospital systems, community physicians, and a community foundation through our well-established and differentiated JV model. Collectively, we operate as a unified organization with a consumer-centric approach to caring for our patients and our communities. Our strategic JV partners offer us significant advantages, including expanded access points, clinical talent availability, local brand recognition, and scale that enable us to accelerate market penetration. We believe that we help our partners enhance their network and regional presence through our operational acumen. We strive to strengthen clinical services, drive operating improvements, and centrally manage operations to optimize hospital performance and enhance patient care. In each of these partnerships, we are the majority owner and serve as the day-to-day operator.
Our principal executive offices are located at 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027, and our telephone number is (615) 296-3000. Our website address is www.ardenthealth.com, and the information contained on, or accessible from, or hyperlinked to, our website and our facilities’ websites is not part of this prospectus supplement or the accompanying prospectus.
Concurrent share repurchase
Subject to the completion of this offering, we intend to concurrently repurchase from the underwriters up to 1,500,000 of the shares of our common stock that are the subject of this offering at a price per share equal to the price at which the underwriters will purchase the shares from the selling stockholders. We refer to this transaction as the “Concurrent Share Repurchase.” Following the closing of the Concurrent Share Repurchase, we intend to cancel the shares we repurchase from the underwriters.
The Concurrent Share Repurchase was reviewed and approved by our board of directors and the Audit Committee of our board of directors in November 2026. We intend to fund the Concurrent Share Repurchase with cash on hand. The underwriters will not receive any compensation for the shares being repurchased by us. The Concurrent Share Repurchase is not being made pursuant to the Company’s previously disclosed stock repurchase plan and will not reduce available repurchase capacity thereunder.
This description and the other information in this prospectus supplement regarding the Concurrent Share Repurchase are included in this prospectus supplement solely for informational purposes. This offering is not conditioned upon the completion of the Concurrent Share Repurchase. Nothing in this prospectus supplement
 
S-1

Table of Contents
 
should be construed as an offer to sell, or the solicitation of an offer to buy, any of our common stock subject to the Concurrent Share Repurchase. See “The Concurrent Share Repurchase.”
Our significant stockholder
EGI-AM Investments, L.L.C. (“EGI-AM”) is an affiliated entity of Equity Group Investments (“EGI”). EGI is the private investment firm founded by Sam Zell in 1968. Backed by private capital, EGI is flexible and opportunistic with a focus on control investments in middle-market operating businesses. EGI actively partners with portfolio company management to execute strategic planning, implement operational efficiencies, and scale businesses. EGI has grown companies across numerous industries into multi-billion-dollar businesses throughout economic cycles. EGI’s current portfolio includes investments in healthcare, transportation and logistics, infrastructure, energy, consumer, industrial, manufacturing, and agri-business.
Following the consummation of this offering and the Concurrent Share Repurchase, we will continue to be a “controlled company” under the rules of the NYSE because more than 50% of the voting power of our common stock will be held by EGI-AM. EGI-AM will beneficially own 70,109,780 shares of our common stock and approximately 50.3% of the voting power of our outstanding common stock (or 69,039,272 shares and approximately 49.5% of such voting power if the underwriters exercise in full their option to purchase additional shares of common stock). Pursuant to the terms of the Nomination Agreement, dated July 19, 2024, among us, EGI-AM and ALH Holdings, LLC (the “Nomination Agreement”), following the consummation of this offering and the Concurrent Share Repurchase, EGI-AM will continue to have the right to designate for nomination for election a majority of the total number of our directors (representing at least six of the 11 directors on our board of directors, including the Chairman of our board of directors, following the consummation of this offering and the Concurrent Share Repurchase) as long as EGI-AM beneficially owns at least 50% of the total voting power of the outstanding shares of our common stock. See “Risk Factors—Following the consummation of this offering and the Concurrent Share Repurchase, EGI-AM will continue to hold a significant percentage of our common stock and may have conflicts of interest with other stockholders” and “Risk Factors—We are a “controlled company” within the meaning of the NYSE rules and, as a result, we are eligible to rely on exemptions from certain corporate governance requirements; you may not have the same protections afforded to stockholders of companies that are subject to all such requirements.”
Recent developments
Boone acquisition
On November 12, 2026, we announced that we entered into a definitive agreement (the “Acquisition Agreement”) to acquire Boone Health, a not-for-profit health system based in Columbia, Missouri (the “Boone Acquisition”). Under the terms of the Acquisition Agreement, we will pay cash consideration of $47 million. The Boone Acquisition will include the 392-bed Boone Hospital Center, Boone Health Medical Group, 19 sites of care, related ancillary services and associated real estate. The Boone Acquisition is expected to close in the first quarter of 2027, subject to the satisfaction of customary closing conditions. We cannot assure you that the Boone Acquisition will be completed on the terms or timeline anticipated, or at all.
Stock repurchase plan increase
In November 2025, our board of directors authorized a stock repurchase plan (the “Stock Repurchase Plan”), pursuant to which the Company is authorized to repurchase up to a maximum aggregate amount of $50.0 million of shares of our common stock through open market purchases, privately negotiated transactions, block trades or other transactions in accordance with applicable securities laws, subject to market conditions and other factors. Subsequently, in September 2026, our board of directors authorized a $25.0 million increase to the Stock Repurchase Plan, increasing the aggregate amount of common stock we may repurchase under the Stock Repurchase Plan to $75.0 million. The Stock Repurchase Plan has no expiration date. At September 30, 2026, there was approximately $48.0 million of repurchase authorization remaining under the Stock Repurchase Plan. As noted above, the Concurrent Share Repurchase of up to 1,500,000 of the shares of our common stock that
 
S-2

Table of Contents
 
are the subject of this offering from the underwriters is not being made under the Stock Repurchase Plan and will not reduce available repurchase capacity thereunder.
 
S-3

Table of Contents
 
THE OFFERING
Issuer
Ardent Health, Inc.
Common Stock Offered by the Selling Stockholders
8,000,000 shares of common stock (or 9,200,000 shares of common stock if the underwriters’ option to purchase additional shares of our common stock is exercised in full).
Option to Purchase Additional Shares of Common Stock
The selling stockholders have granted the underwriters an option to purchase up to 1,200,000 additional shares of common stock from the selling stockholders at the public offering price, less underwriting discounts and commissions, within 30 days of the date of this prospectus supplement.
Concurrent Share Repurchase
Subject to the completion of this offering, we intend to concurrently repurchase from the underwriters up to 1,500,000 of the shares of our common stock that are the subject of this offering at a price per share equal to the price at which the underwriters will purchase the shares from the selling stockholders. See “Prospectus Supplement Summary—​Concurrent Share Repurchase” and “The Concurrent Share Repurchase.”
Common Stock to be Outstanding After the Offering and the Concurrent Share Repurchase
139,436,393 shares (assuming that we repurchase 1,500,000 shares in the Concurrent Share Repurchase).
Use of Proceeds
We will not receive any of the proceeds from the sale of our common stock by the selling stockholders in this offering, including any shares the selling stockholders may sell pursuant to the underwriters’ option to purchase additional shares of our common stock.
Risk Factors
Our business is subject to a number of risks that you should consider before making a decision to invest in our common stock. See the “Risk Factors” section of this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein.
Material U.S. Federal Income Tax Considerations for Non-U.S. Holders
For a discussion of certain U.S. federal income tax considerations that may be relevant for non-U.S. stockholders, see “Material U.S. Federal Income Tax Considerations for Non-U.S. Holders.”
NYSE Trading Symbol
“ARDT.”
The number of shares of our common stock to be outstanding immediately following this offering and the Concurrent Share Repurchase is based on 140,936,393 shares of common stock outstanding as of November 2, 2026 and (i) reflects the repurchase and cancellation of 1,500,000 shares of common stock in the Concurrent Share Repurchase and (ii) excludes:
•
6,742,424 shares of common stock reserved for future issuance under our 2024 Omnibus Incentive Award Plan;
​
​
 
S-4

Table of Contents
 
•
1,928,983 shares of common stock issuable upon the vesting and settlement of outstanding time-based restricted stock units; and
​
•
2,582,036 shares of common stock issuable upon the vesting and settlement of outstanding performance-based restricted stock units.
​
Unless otherwise indicated, all information in this prospectus supplement:
•
assumes no exercise by the underwriters of their option to purchase additional shares of common stock; and
​
•
assumes that we repurchase 1,500,000 shares of our common stock in the Concurrent Share Repurchase.
​
​
 
S-5

Table of Contents​
 
RISK FACTORS
Investing in our common stock involves a high degree of risk. Our reputation, business, financial position, results of operations and cash flows are subject to various risks. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this prospectus supplement, the accompanying prospectus or incorporated by reference herein and therein, including the risks and uncertainties discussed under the heading “Risk Factors” in the accompanying prospectus and under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent Quarterly Reports on Form 10-Q and our audited and unaudited consolidated financial statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us could materially and adversely affect our reputation, business, financial position, results of operations or cash flows. In such case, the market price of our common stock could decline, and you may lose all or part of your investment. This prospectus supplement also contains forward-looking statements and estimates that involve risks and uncertainties. See “Cautionary Language Regarding Forward-Looking Statements.” Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.
Risks Related to Our Common Stock and This Offering
Our stock price could be volatile, and, as a result, our stockholders may not be able to resell their shares at or above the price paid for them.
The price of our common stock has fluctuated and could continue to be subject to fluctuations in response to a number of factors, including the following factors and those described elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein:
•
United States political and economic factors unrelated to our performance;
​
•
market conditions in the broader stock market;
​
•
actual or anticipated fluctuations in our annual and quarterly financial and operating results;
​
•
introduction of new products or services by us or our competitors;
​
•
speculation in the press or investment community;
​
•
issuance of new or changed securities analysts’ reports or recommendations;
​
•
our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market;
​
•
results of operations that vary from expectations of securities analysts and investors;
​
•
guidance, if any, that we may provide to the public, any changes in this guidance or our failure to meet this guidance;
​
•
strategic actions by us or our competitors;
​
•
announcement by us or our competitors of significant contracts or acquisitions;
​
•
sales, or anticipated sales, of large blocks of our shares of common stock;
​
•
additions or departures of key personnel;
​
•
regulatory, legal or political developments;
​
•
tax developments;
​
•
public response to press releases or other public announcements by us or third parties, including our filings with the SEC;
​
 
S-6

Table of Contents
 
•
litigation and governmental investigations;
​
•
changing economic conditions;
​
•
changes in accounting principles;
​
•
default under agreements governing our indebtedness;
​
•
exchange rate fluctuations; and
​
•
other events or factors, including those from natural disasters, war, acts of terrorism, periods of widespread civil unrest or responses to these events.
​
Future sales, or the perception of future sales, by us or our stockholders could cause the market price for our common stock to decline.
The sale of our common stock, or the perception that such sales could occur, could harm the prevailing market price of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.
The 70,109,780 shares of our common stock held by EGI-AM following the consummation of this offering and the Concurrent Share Repurchase will represent approximately 50.3% of our total outstanding common stock following this offering and the Concurrent Share Repurchase (or 49.5% if the underwriters’ option to purchase additional shares of our common stock is exercised in full). Such shares of common stock, together with shares held by certain of our directors, executive officers and other affiliates, as that term is defined under Rule 144 (“Rule 144”) of the Securities Act of 1933, as amended (the “Securities Act”), are subject to certain restrictions on resale under federal securities laws. Such securities may be sold in the public market only if they are registered under the Securities Act or are sold pursuant to an exemption from registration such as Rule 144.
In connection with this offering, we, our directors and executive officers and the selling stockholders have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for common stock during the period from the date of the lock-up agreements continuing through the date that is 90 days after the date of this prospectus supplement, except with the prior written consent of J.P. Morgan Securities LLC and Barclays Capital Inc. See “Underwriting” for a description of these lock-up agreements.
Pursuant to a Registration Rights Agreement, EGI-AM and certain other significant stockholders have certain registration rights with respect to our common stock. Registration of any of these outstanding shares of common stock would result in such shares becoming freely tradable without compliance with Rule 144 upon effectiveness of the registration statement. If EGI-AM or another stockholder exercises its registration rights, the market price of our common stock could drop significantly if the holders of these shares sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our common stock or other securities.
We may also issue our securities in connection with investments or acquisitions. The amount of our common stock issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding common stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to our stockholders and the securities issued may have rights that are senior to our common stock.
Following the consummation of this offering and the Concurrent Share Repurchase, EGI-AM will continue to hold a significant percentage of our common stock and may have conflicts of interest with other stockholders.
Following the consummation of this offering and the Concurrent Share Repurchase, EGI-AM will own approximately 50.3% of the outstanding shares of our common stock (or approximately 49.5% if the underwriters exercise in full their option to purchase additional shares), assuming that we repurchase 1,500,000 shares of our common stock. EGI-AM will continue to have significant governance rights, including the right to nominate a majority of
 
S-7

Table of Contents
 
our directors, and will continue to have the ability to significantly influence the approval or disapproval of substantially all transactions and other matters requiring approval by stockholders, including the election of directors.
Pursuant to the terms of the Nomination Agreement, following the consummation of this offering and the Concurrent Share Repurchase, EGI-AM will continue to have the right to designate for nomination for election a majority of the total number of our directors (representing at least six of the 11 directors on our board of directors, including the Chairman of our board of directors, following the consummation of this offering and the Concurrent Share Repurchase) as long as EGI-AM beneficially owns at least 50% of the total voting power of the outstanding shares of our common stock. In addition, following the consummation of this offering and the Concurrent Share Repurchase, ALH Holdings, LLC will continue to have the right to designate one director for nomination for election as long as ALH Holdings, LLC and any of its affiliates (including Ventas, Inc.) together beneficially own 4% or more of the total voting power of the outstanding shares of our common stock. The Nomination Agreement also provides that, for so long as EGI-AM has such nomination rights, our board of directors must use reasonable best efforts to cause any committee of our board of directors to include in its membership at least one director nominated by EGI-AM, provided that, in each case, such individual satisfies all applicable SEC and stock exchange requirements (after taking into account all available exemptions under the rules of the applicable stock exchange).
Because EGI-AM’s interests may differ from your interests, actions EGI-AM takes as a significant stockholder may not be favorable to you. For example, the concentration of ownership held by EGI-AM could delay, defer or prevent a change of control of us or impede a merger, takeover or other business combination that another stockholder may otherwise view favorably. Other potential conflicts could arise, for example, over matters such as employee retention or recruiting, or our dividend policy.
Future offerings of debt or equity securities that rank senior to our common stock, or common stock or other securities convertible or exchangeable into common or preferred stock, in connection with a financing, strategic investment, litigation settlement, employee arrangement or otherwise, may result in dilution to owners of our common stock and/or may adversely affect the market price of our common stock.
If, in the future, we decide to issue debt or equity securities that rank senior to our common stock, it is likely that such securities will be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Issuing additional shares of our common stock or other equity securities or securities convertible into, exercisable for or exchangeable for common or preferred stock, in connection with a financing, strategic investment, litigation settlement, employee arrangement or otherwise, may dilute the economic and voting rights of our stockholders and reduce the market price of our common stock. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in substantial dilution to our existing stockholders. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred stock, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of our common stock. We and, indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors outside our control, we cannot predict or estimate the amount, timing or nature of any future offerings. Thus, holders of our common stock will bear the risk of any such future offerings reducing the market price of our common stock, diluting the value of their stock holdings in us, and/or having any of the other consequences described above.
We are a “controlled company” within the meaning of the NYSE rules and, as a result, we are eligible to rely on exemptions from certain corporate governance requirements; you may not have the same protections afforded to stockholders of companies that are subject to all such requirements.
We are a “controlled company” within the meaning of the corporate governance standards of the NYSE. Following this offering and the Concurrent Share Repurchase, EGI-AM will continue to hold more than 50% of the voting
 
S-8

Table of Contents
 
power for the election of our directors and, accordingly, we will continue to qualify as a “controlled company” under the NYSE rules. Under these rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain corporate governance requirements, including the requirements that:
•
we have a board of directors that is composed of a majority of independent directors, as defined under the listing rules of the NYSE;
​
•
we have a compensation committee that is composed entirely of independent directors; and
​
•
our director nominations be made, or recommended to our full board of directors, by our independent directors or by a nominating and corporate governance committee that consists entirely of independent directors.
​
We are eligible to rely on these exemptions as long as we continue to qualify as a “controlled company.” Accordingly, you may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the NYSE. Our status as a “controlled company” could make our common stock less attractive to some investors or otherwise harm the trading price of our common stock.
The 1% U.S. federal excise tax could be imposed on us in connection with the Concurrent Share Repurchase and future redemptions by us of our shares.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a non-deductible U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. Accordingly, if the Concurrent Share Repurchase is consummated, we may be subject to this excise tax in connection with the Concurrent Share Repurchase (and with other repurchases of our shares, regardless of whether the Concurrent Share Repurchase is consummated), subject to applicable exceptions and reductions, including the netting of certain stock issuances occurring during the same taxable year.
 
S-9

Table of Contents​
 
THE CONCURRENT SHARE REPURCHASE
Subject to the completion of this offering, we intend to concurrently repurchase from the underwriters up to 1,500,000 of the shares of our common stock that are the subject of this offering at a price per share equal to the price at which the underwriters will purchase the shares from the selling stockholders. Following the closing of the Concurrent Share Repurchase, we intend to cancel the shares we repurchase from the underwriters.
The Concurrent Share Repurchase was reviewed and approved by our board of directors and the Audit Committee of our board of directors in November 2026. We intend to fund the Concurrent Share Repurchase with cash on hand. The underwriters will not receive any compensation for the shares being repurchased by us. The Concurrent Share Repurchase is not being made pursuant to the Company’s previously disclosed stock repurchase plan and will not reduce available repurchase capacity thereunder.
Although the closing of the Concurrent Share Repurchase is conditioned on the closing of this offering, the closing of this offering is not conditioned upon the closing of the Concurrent Share Repurchase, and there can be no assurances that the Concurrent Share Repurchase will be completed even if this offering is completed.
This description and the other information in this prospectus supplement regarding the Concurrent Share Repurchase are included in this prospectus supplement solely for informational purposes. Nothing in this prospectus supplement should be construed as an offer to sell, or the solicitation of an offer to buy, any of our common stock subject to the Concurrent Share Repurchase.
 
S-10

Table of Contents​
 
USE OF PROCEEDS
The selling stockholders are selling all of the common stock being sold in this offering, including any shares of common stock sold upon the exercise of the underwriters’ option to purchase additional shares. Accordingly, we will not receive any proceeds from the sale of shares of our common stock being sold in this offering. We will bear the costs associated with the sale of the shares in this offering by the selling stockholders, other than underwriting discounts and commissions. See “Underwriting” and “Selling Stockholders.”
 
S-11

Table of Contents​
 
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS
The following is a discussion of certain U.S. federal income tax considerations relating to the purchase, ownership and disposition of our common stock by Non-U.S. Holders (as defined below) that purchase such common stock pursuant to this offering and hold such common stock as a capital asset. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), U.S. Treasury regulations promulgated or proposed thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation. This discussion does not address all of the U.S. federal income tax considerations that may be relevant to specific Non-U.S. Holders in light of their particular circumstances or to Non-U.S. Holders subject to special treatment under U.S. federal income tax law (such as banks, insurance companies, dealers in securities or other Non-U.S. Holders that generally mark their securities to market for U.S. federal income tax purposes, foreign governments, international organizations, tax-exempt entities, certain former citizens or residents of the United States, or Non-U.S. Holders that hold our common stock as part of a straddle, hedge, conversion or other integrated transaction). This discussion does not address any U.S. state or local or non-U.S. tax considerations or any U.S. federal gift or alternative minimum tax considerations.
As used in this discussion, the term “Non-U.S. Holder” means a beneficial owner of our common stock that, for U.S. federal income tax purposes, is:
•
an individual who is neither a citizen nor a resident of the United States;
​
•
a corporation that is not created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;
​
•
an estate that is not subject to U.S. federal income tax on income from non-U.S. sources which is not effectively connected with the conduct of a trade or business in the United States; or
​
•
a trust unless (i) a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions or (ii) it has in effect a valid election under applicable U.S. Treasury regulations to be treated as a U.S. person.
​
If an entity treated as a partnership for U.S. federal income tax purposes invests in our common stock, the U.S. federal income tax considerations relating to such investment will depend in part upon the status and activities of such entity and the particular partner. Any such entity should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners relating to the purchase, ownership and disposition of our common stock.
PERSONS CONSIDERING AN INVESTMENT IN OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. INCOME, ESTATE AND OTHER TAX CONSIDERATIONS RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES.
Distributions on Common Stock
If we make a distribution of cash or other property (other than certain pro rata distributions of our common stock or rights to acquire our common stock) with respect to a share of our common stock, the distribution generally will be treated as a dividend to the extent it is paid from our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). If the amount of such distribution exceeds our current and accumulated earnings and profits, such excess generally will be treated first as a tax-free return of capital to the extent of the Non-U.S. Holder’s adjusted tax basis in such share of our common stock, and then as capital gain (which will be treated in the manner described below under “Sale, Exchange or Other Disposition of common stock”). Distributions treated as dividends on our common stock that are paid to or for the account of a Non-U.S. Holder generally will be subject to U.S. federal withholding tax at a rate of 30%, or at a lower rate if provided by an applicable tax treaty and the Non-U.S. Holder provides the documentation (generally, Internal Revenue Service (“IRS”) Form W-8BEN or W-8BEN-E) required to claim benefits under such tax treaty to the applicable
 
S-12

Table of Contents
 
withholding agent. Even if our current or accumulated earnings and profits are less than the amount of the distribution, the applicable withholding agent may elect to treat the entire distribution as a dividend for U.S. federal withholding tax purposes. Each Non-U.S. Holder should consult its own tax advisor regarding U.S. federal withholding tax on distributions, including such Non-U.S. Holder’s eligibility for a lower rate and the availability of a refund of any excess U.S. federal tax withheld.
If, however, a dividend is effectively connected with the conduct of a trade or business in the United States by a Non-U.S. Holder (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), such dividend generally will not be subject to the 30% U.S. federal withholding tax if such Non-U.S. Holder provides the appropriate documentation (generally, IRS Form W-8ECI) to the applicable withholding agent. Instead, such Non-U.S. Holder generally will be subject to U.S. federal income tax on such dividend in substantially the same manner as a U.S. person (except as provided by an applicable tax treaty). In addition, a Non-U.S. Holder that is treated as a corporation for U.S. federal income tax purposes may be subject to a branch profits tax at a rate of 30% (or a lower rate if provided by an applicable tax treaty) on its effectively connected income for the taxable year, subject to certain adjustments.
The foregoing discussion is subject to the discussion below under “—FATCA Withholding” and “—Information Reporting and Backup Withholding.”
Sale, Exchange or Other Disposition of Common Stock
A Non-U.S. Holder generally will not be subject to U.S. federal income tax on any gain recognized on the sale, exchange or other disposition of our common stock unless:
1. such gain is effectively connected with the conduct of a trade or business in the United States by such Non-U.S. Holder, in which event such Non-U.S. Holder generally will be subject to U.S. federal income tax on such gain in substantially the same manner as a U.S. person (except as provided by an applicable tax treaty) and, if it is treated as a corporation for U.S. federal income tax purposes, may also be subject to a branch profits tax at a rate of 30% (or a lower rate if provided by an applicable tax treaty);
2. such Non-U.S. Holder is an individual who is present in the United States for 183 days or more during the taxable year of such sale, exchange or other disposition and certain other conditions are met, in which event such gain (net of certain U.S. source losses, provided that such Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses) generally will be subject to U.S. federal income tax at a rate of 30% (except as provided by an applicable tax treaty); or
3. we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of (x) the five-year period ending on the date of such sale, exchange or other disposition and (y) such Non-U.S. Holder’s holding period with respect to such common stock, and certain other conditions are met.
Generally, a corporation is a “United States real property holding corporation” if the fair market value of its United States real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business (all as determined for U.S. federal income tax purposes). We believe that we presently are not, and we do not presently anticipate that we will become, a United States real property holding corporation. However, even if we are, have been or were to become a United States real property holding corporation, so long as our common stock is “regularly traded” as defined by applicable U.S. Treasury regulations, on an established securities market, a Non-U.S. Holder generally will not be subject to U.S. federal income tax under these rules on gain recognized from the sale, exchange or other disposition of our common stock unless such Non-U.S. Holder has owned, directly, indirectly or constructively, more than 5% of our common stock at any time during the applicable period described above.
The foregoing discussion is subject to the discussion below under “—Information Reporting and Backup Withholding.”
 
S-13

Table of Contents
 
FATCA Withholding
Under the Foreign Account Tax Compliance Act (“FATCA”) provisions of the Code and related U.S. Treasury guidance (including proposed regulations on which taxpayers are permitted to rely pending finalization), a withholding tax of 30% will be imposed in certain circumstances on payments of dividends on our common stock. In the case of payments made to a “foreign financial institution” ​(such as a bank, a broker, an investment fund or, in certain cases, a holding company), as a beneficial owner or as an intermediary, this tax generally will be imposed, subject to certain exceptions, unless such institution (i) has agreed to (and does) comply with the requirements of an agreement with the United States (an “FFI Agreement”) or (ii) is required by (and does comply with) applicable foreign law enacted in connection with an intergovernmental agreement between the United States and a foreign jurisdiction (an “IGA”) to, among other things, collect and provide to the U.S. tax authorities or other relevant tax authorities certain information regarding U.S. account holders of such institution and, in either case, such institution provides the withholding agent with a certification as to its FATCA status. In the case of payments made to a foreign entity that is not a financial institution (as a beneficial owner), the tax generally will be imposed, subject to certain exceptions, unless such entity provides the withholding agent with a certification as to its FATCA status and, in certain cases, either certifies it does not have any “substantial” U.S. owner (generally, any specified U.S. person that directly or indirectly owns more than a specified percentage of such entity) or furnishes identifying information regarding each “substantial” U.S. owner. If our common stock is held through a foreign financial institution that has agreed to comply with the requirements of an FFI Agreement or is subject to similar requirements under applicable foreign law enacted in connection with an IGA, such foreign financial institution (or, in certain cases, a person paying amounts to such foreign financial institution) generally will be required, subject to certain exceptions, to withhold tax on payments made to (i) a person (including an individual) that fails to provide any required information or documentation or (ii) a foreign financial institution that has not agreed to comply with the requirements of an FFI Agreement and is not subject to similar requirements under applicable foreign law enacted in connection with an IGA. Each Non-U.S. Holder should consult its own tax advisor regarding the application of FATCA to our common stock.
Information Reporting and Backup Withholding
Distributions on our common stock made to a Non-U.S. Holder and the amount of any U.S. federal tax withheld from such distributions generally will be reported annually to the IRS and to such Non-U.S. Holder by the applicable withholding agent.
Backup withholding rules generally will not apply to payments of dividends on our common stock to a Non-U.S. Holder if such Non-U.S. Holder certifies under penalties of perjury that it is not a U.S. person (generally by providing an IRS Form W-8BEN or W-8BEN-E to the applicable withholding agent) or otherwise establishes an exemption.
Proceeds from the sale, exchange or other disposition of our common stock by a Non-U.S. Holder effected outside the United States through a non-U.S. office of a non-U.S. broker generally will not be subject to the information reporting or backup withholding rules, provided that the proceeds are paid to the Non-U.S. Holder outside the United States. However, proceeds from the sale, exchange or other disposition of our common stock by a Non-U.S. Holder effected through a non-U.S. office of a non-U.S. broker with certain specified U.S. connections or of a U.S. broker generally will be subject to these information reporting rules (but generally not to these backup withholding rules), even if the proceeds are paid to such Non-U.S. Holder outside the United States, unless such Non-U.S. Holder certifies under penalties of perjury that it is not a U.S. person (generally by providing an IRS Form W-8BEN or W-8BEN-E to the applicable withholding agent) or otherwise establishes an exemption. Proceeds from the sale, exchange or other disposition of our common stock by a Non-U.S. Holder effected through a U.S. office of a broker generally will be subject to these information reporting and backup withholding rules unless such Non-U.S. Holder certifies under penalties of perjury that it is not a U.S. person (generally by providing an IRS Form W-8BEN or W-8BEN-E to the applicable withholding agent) or otherwise establishes an exemption.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a Non-U.S. Holder’s U.S. federal income tax liability if the required information is furnished by such Non-U.S. Holder on a timely basis to the IRS.
 
S-14

Table of Contents​
 
SELLING STOCKHOLDERS
The following table sets forth information as of November 2, 2026 with respect to the beneficial ownership of our common stock by the selling stockholders. The amounts and percentages of shares beneficially owned are reported on the basis of SEC regulations governing the determination of beneficial ownership of securities. Under SEC rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days of the determination date. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person’s ownership percentage, but not for purposes of computing any other person’s ownership percentage. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest.
The beneficial ownership percentages shown in the table prior to this offering are based upon 140,936,393 shares of our common stock outstanding as of November 2, 2026. The beneficial ownership percentages shown in the table immediately following the consummation of this offering are based upon 139,436,393 shares of our common stock outstanding after giving effect to the repurchase of 1,500,000 shares of our common stock in the Concurrent Share Repurchase.
Except as otherwise indicated in the footnotes to this table, the beneficial owner listed has, to our knowledge, sole voting and investment power with respect to the indicated shares of common stock.
​ ​ ​
Shares of common stock
​
Name of beneficial owner
​ ​
Beneficially
owned
before the
offering
and the
concurrent
share
repurchase
​ ​
Offered,
assuming
underwriters’
option is
not exercised
​ ​
Beneficially
Owned After
the Offering
and the
Concurrent
Share
Repurchase,
Assuming
Underwriters’
Option is
Not
Exercised
​ ​
Offered,
Assuming
Underwriters’
Option is
Exercised
in Full
​ ​
Beneficially
Owned After
the Offering
and the
Concurrent
Share
Repurchase,
Assuming
Underwriters’
Option is
Exercised in
Full
​
​
Number
​ ​
%
​ ​
Number
​ ​
Number
​ ​
%
​ ​
Number
​ ​
Number
​ ​
%
​
EGI-AM Investments, L.L.C.(1)(3)
​ ​ ​ ​ 77,246,499 ​ ​ ​ ​ ​ 54.8% ​ ​ ​ ​ ​ 7,136,719 ​ ​ ​ ​ ​ 70,109,780 ​ ​ ​ ​ ​ 50.3% ​ ​ ​ ​ ​ 8,207,227 ​ ​ ​ ​ ​ 69,039,272 ​ ​ ​ ​ ​ 49.5% ​ ​
ALH Holdings, LLC(2)(3)
​ ​ ​ ​ 9,342,501 ​ ​ ​ ​ ​ 6.6% ​ ​ ​ ​ ​ 863,281 ​ ​ ​ ​ ​ 8,479,220 ​ ​ ​ ​ ​ 6.1% ​ ​ ​ ​ ​ 992,773 ​ ​ ​ ​ ​ 8,349,728 ​ ​ ​ ​ ​ 6.0% ​ ​
(1) Each of EGI-AM Investor, L.L.C., the manager of EGI-AM, and Chai Trust Company, LLC, the managing member of EGI-AM Investor, L.L.C., shares voting and dispositive power over the 77,246,499 shares held by EGI-AM. The address of these entities is Two North Riverside Plaza, Suite 600, Chicago, Illinois 60606.
(2) Ventas, Inc. (“Ventas”), as the general partner of Ventas Realty, Limited Partnership, the sole and managing member of VTR AMS, LLC, the sole and managing member of ALH Holdings, LLC, has voting and dispositive power over the 9,342,501 shares held by ALH Holdings, LLC. The address for Ventas is 300 N LaSalle St., Suite 1600, Chicago, Illinois 60654.
(3) For information regarding certain material relationships between the selling stockholders and the Company, see “Certain Relationships and Related Party Transactions” included in our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 8, 2026, portions of which are incorporated by reference in this prospectus supplement and the accompanying prospectus.
 
S-15

Table of Contents​
 
Underwriting
The selling stockholders are offering the shares of common stock described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities LLC and Barclays Capital Inc. are acting as bookrunning managers of the offering and representatives of the underwriters. The Company and the selling stockholders will enter into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, the selling stockholders have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table:
Underwriter
​ ​
Number of shares
​
J.P. Morgan Securities LLC
​ ​ ​ ​ ​ ​ ​
Barclays Capital Inc.
​ ​ ​ ​ ​ ​ ​
BofA Securities, Inc.
​ ​ ​ ​ ​ ​ ​
Citigroup Global Markets Inc.
​ ​ ​ ​ ​ ​ ​
Leerink Partners LLC
​ ​ ​ ​ ​ ​ ​
Mizuho Securities USA LLC
​ ​ ​ ​ ​ ​ ​
RBC Capital Markets, LLC
​ ​ ​ ​ ​ ​ ​
Stephens Inc.
​ ​ ​ ​ ​ ​ ​
Truist Securities, Inc.
​ ​ ​ ​ ​ ​ ​
Capital One Securities, Inc.
​ ​ ​ ​ ​ ​ ​
Total
​ ​ ​ ​ 8,000,000 ​ ​
The underwriters are committed to purchase all the shares of common stock offered by the selling stockholders if they purchase any shares, other than those shares covered by the underwriters’ option to purchase additional shares described below. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated.
Subject to the completion of this offering, we intend to concurrently repurchase from the underwriters up to 1,500,000 of the shares of our common stock that are the subject of this offering at a price per share equal to the price at which the underwriters will purchase the shares from the selling stockholders. Following the closing of the Concurrent Share Repurchase, we intend to cancel the shares we repurchase from the underwriters. See “Prospectus Supplement Summary—Concurrent Share Repurchase” and “The Concurrent Share Repurchase.”
The underwriters have an option to purchase on a pro rata basis up to 1,200,000 additional shares of common stock from the selling stockholders at the public offering price less the underwriting discounts and commissions. The underwriters have 30 days from the date of this prospectus supplement to exercise this option. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares that are not subject to the Concurrent Share Repurchase are being offered.
The underwriters propose to offer the common shares that are not subject to the Concurrent Share Repurchase directly to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of $      per share. After the public offering of such shares, the offering price and other selling terms may be changed by the underwriters. The offering of such shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part. The underwriters may offer and sell such shares through certain of their affiliates or other registered broker-dealers or selling agents. Sales of shares made outside of the United States may be made by affiliates of the underwriters.
The underwriting fee is the difference between the public offering price and the amount the underwriters pay the selling stockholders for the shares of common stock. The underwriting fee is $      per share. The following
 
S-16

Table of Contents
 
table summarizes the per share and total underwriting discounts and commissions the selling stockholders will pay to the underwriters. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares of common stock from the selling stockholders.
​ ​ ​ ​ ​ ​
Total
​
​ ​ ​
Per share
​ ​
No exercise
​ ​
Full exercise
​
Public offering price(1)
​ ​ ​ $ ​ ​ ​ ​ $ ​ ​ ​ ​ $ ​ ​
Underwriting discounts and commissions borne by the selling stockholders(1)
​ ​ ​ $          ​ ​ ​ ​ $          ​ ​ ​ ​ $          ​ ​
(1) Total public offering price and total underwriting discounts and commissions borne by the selling stockholders do not include the shares of our common stock to be repurchased by us from the underwriters pursuant to the Concurrent Share Repurchase.
We estimate that the total expenses of this offering, including filing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, are approximately $1.0 million. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $15,000. The selling stockholders will bear the underwriting discounts and commissions attributable to their sale of our common stock.
A prospectus in electronic format may be made available on the websites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make internet distributions on the same basis as other allocations.
We have agreed that we will not, and will not publicly disclose an intention to, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our common stock or any securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Barclays Capital Inc. for a period of 90 days after the date of this prospectus supplement (such period, the “Restricted Period”).
The restrictions set forth above applicable to us are subject to specified exceptions, including:
(i) the issuance of shares of common stock or securities convertible into or exercisable for common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (“RSUs”) (including net settlement), in each case, outstanding on the date of this prospectus supplement and as described in this prospectus supplement or the documents incorporated herein by reference;
(ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of common stock or securities convertible into or exercisable or exchangeable for common stock (whether upon the exercise of stock options or otherwise) to the Company’s current or former employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan of the Company in effect as of the closing of this offering and as described in this prospectus supplement or the documents incorporated herein by reference, provided that such recipients enter into a lock-up agreement;
(iii) the issuance of common stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, common stock, in connection with the acquisition by the Company or any of its subsidiaries of the assets of, or a majority or controlling portion of the equity of, or a business combination or a joint venture with, another entity or other similar strategic transactions and the filing with or confidential submission to the SEC of
 
S-17

Table of Contents
 
a registration statement in connection therewith, provided that the aggregate number of shares of common stock that the Company may issue pursuant to this clause (iii) shall not exceed 10% of the total number of common stock issued and outstanding immediately following this offering and any such recipients shall execute and deliver to J.P. Morgan Securities LLC and Barclays Capital Inc. a lock-up agreement prior to or concurrent with such issuance;
(iv) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any plan in effect on the date of this prospectus supplement and described in this prospectus supplement, the documents incorporated herein by reference or in any assumed benefit plan pursuant to an acquisition or similar strategic transaction;
(v) facilitating the establishment of trading plans pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the extent permitted by the lock-up agreements; and
(vi) the confidential submission of a registration statement with the SEC under the Securities Act relating to any Lock-Up Securities (as defined below); provided that, with respect to this clause (vi), (i) such confidential submission is made after 75 days after the date of this prospectus supplement, (ii) no public filing with the SEC or any other public announcement may be made during the Restricted Period in relation to such registration, (iii) J.P. Morgan Securities LLC and Barclays Capital Inc. must have received prior written notice from the Company of a confidential submission of a registration statement with the SEC during the Restricted Period at least seven business days prior to such submission and (iv) such registration shall not result in an offer, sale, contract to sell, pledge, option to purchase, short sale or other transfer or disposition of, directly or indirectly, any Lock-Up Securities during the Restricted Period.
Our directors, executive officers and the selling stockholders (such persons, the “lock-up parties”) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for the Restricted Period, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Barclays Capital Inc., (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, our common stock or such other securities which may be deemed to be beneficially owned by such lock-up parties in accordance with the rules and regulations of the SEC, securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the “Lock-Up Securities”)), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of the Lock-Up Securities, in cash or otherwise, (3) make any demand for, or exercise any right with respect to, the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing.
The restrictions set forth above applicable to any lock-up parties are subject to specified exceptions, including:
(a) transfer, distribution, or cause of disposition of (as the case may be) the Lock-Up Securities:
(i) as a bona fide gift or gifts, charitable contribution or contributions, or for bona fide estate planning purposes,
(ii) by will, other testamentary document or intestacy,
(iii) to any member of the lock-up party’s immediate family or to any trust for the direct or indirect benefit of the lock-up party or the immediate family of the lock-up party, or if the lock-up party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (“immediate family” shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),
 
S-18

Table of Contents
 
(iv) to a corporation, partnership, limited liability company or other entity of which the lock-up party and/or one or more of the immediate family members of the lock-up party are the legal or beneficial owner of all of the outstanding equity securities or similar interests,
(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,
(vi) if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the lock-up party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the lock-up party or affiliates of the lock-up party (including, for the avoidance of doubt, where the lock-up party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution to partners, members, managers, stockholders or other equityholders or limited partners of the lock-up party, including, in each case, to the estates of any of the foregoing,
(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement,
(viii) to the Company from an employee or consultant of the Company upon death, disability or termination of employment, in each case, of such employee or consultant,
(ix) as part of a sale of the lock-up party’s Lock-Up Securities acquired in open market transactions after the closing date of this offering,
(x) to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of common stock (including, in each case, by way of “net” or “cashless” exercise), including for the payment of exercise price and/or tax and remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of common stock received upon such vesting, settlement or exercise shall be subject to the terms of the lock-up agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the lock-up party pursuant to either an agreement or an equity award granted under a stock incentive plan or other equity award plan, as the case may be, each such agreement or plan which is described in this prospectus supplement or the documents incorporated herein by reference, and
(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the board of directors of the Company and made to all holders of the Company’s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the lock-up party’s Lock-Up Securities shall remain subject to the provisions of the lock-up agreement;
provided that (A) in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) or (vii), such transfer shall not involve a disposition for value (it being understood that, in the case of the selling stockholders, any such transfer pursuant to clause (a)(vi)(A) in which the transferor receives only equity interests of the transferee shall not be deemed to involve a disposition for value) and each donee, devisee, transferee or distributee shall execute and deliver to J.P. Morgan Securities LLC and Barclays Capital Inc. a lock-up letter in the form of the lock-up agreement, (B) in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) or (ix), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in
 
S-19

Table of Contents
 
connection with such transfer or distribution (other than (x) a required filing on a Form 5 made after the expiration of the Restricted Period, (y) a required filing on a Form 4 that discloses therein that such transfer is a disposition by bona fide gift or otherwise a disposition for no value (and if the transferee is a person, trust or entity that would report a corresponding acquisition of such securities on the lock-up party’s Form 4, and such acquisition is entitled to be reported on a Form 5, such acquisition may be voluntarily reported on such Form 4), or (z) a required filing on Schedule 13D, Schedule 13G or Schedule 13G/A; provided, that such filings are made after the expiration of the Restricted Period) and (C) in the case of any transfer or distribution pursuant to clause (a)(vii), (viii) or (x), it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a change in beneficial ownership of shares of common stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer;
(b) exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans or any other equity compensation arrangements described in this prospectus supplement or the documents incorporated herein by reference; provided that any Lock-Up Securities received upon such exercise, vesting or settlement shall be subject to the terms of the lock-up agreement;
(c) convert outstanding preferred stock, warrants to acquire preferred stock or convertible securities into shares of common stock or warrants to acquire shares of common stock; provided that any such shares of common stock or warrants received upon such conversion shall be subject to the terms of the lock-up agreement;
(d) establish trading plans pursuant to Rule 10b5-1 under the Exchange Act (“10b5-1 Plans”) for the transfer of shares of Lock-Up Securities; provided that (1) such 10b5-1 Plans do not provide for the transfer of Lock-Up Securities during the Restricted Period and (2) no filing by any party under the Exchange Act or other public announcement shall be required or made voluntarily in connection with the establishment of such 10b5-1 Plan (other than the required disclosure on Form 10-Q or Form 10-K, as applicable, of the entrance into any 10b5-1 Plan during the relevant fiscal quarter, provided that such disclosure includes a statement to the effect that no transfers may be made pursuant to such 10b5-1 Plan during the Restricted Period);
(e) in connection with the sale of shares of common stock made by virtue of a 10b5-1 Plan that was entered into by the lock-up party prior to the date of the lock-up agreement, provided that the existence and details of such 10b5-1 Plan were communicated to J.P. Morgan Securities LLC and Barclays Capital Inc. or their counsel prior to the execution of the lock-up agreement, such 10b5-1 Plan will not be amended or modified during the Restricted Period and provided, further, that no public filing, report or announcement shall be voluntarily made in connection with such sale, and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a change in beneficial ownership of shares of common stock in connection with such sale shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto that such sale occurred pursuant to a 10b5-1 Plan;
(f) to the extent the lock-up party has demand and/or piggyback registration rights that may be exercised, make any demand or requests for, exercise any right with respect to, or take any action in preparation of the registration by the Company under the Securities Act of the lock-up party’s Lock-Up Securities or other securities; provided that (i) no public filing with the SEC or any other public announcement is made during the Restricted Period in relation to such registration, (ii) J.P. Morgan Securities LLC and Barclays Capital Inc. must have received prior written notice from the Company and/or the lock-up party of a confidential submission of a registration statement with the SEC during the Restricted Period at least seven (7) business days prior to such submission and (iii) no Lock-Up Securities or other securities of the Company are sold, distributed or exchanged prior to the expiration of the Restricted Period; and
(g) in the case of the selling stockholders, the sale of the securities to be sold by the lock-up party pursuant to the terms of the underwriting agreement.
In addition, notwithstanding the lock-up restrictions described above, one of our executive officers may sell up to 100,000 shares of our common stock, commencing on the earlier of (i) 14 days after the date of the underwriting
 
S-20

Table of Contents
 
agreement and (ii) the day following the full exercise of the underwriters’ option to purchase additional shares of common stock from the selling stockholders.
J.P. Morgan Securities LLC and Barclays Capital Inc., in their sole discretion, may release the securities subject to any of the lock-up agreements with the underwriters described above, in whole or in part at any time.
We and the selling stockholders have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act, or contribute payments that the underwriters may be required to make in that respect.
Our common stock is listed on the NYSE under the symbol “ARDT.”
The underwriters have advised us and the selling stockholders that, in connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be “covered” shorts, which are short positions in an amount not greater than the underwriters’ option to purchase additional shares referred to above, or may be “naked” shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position.
The underwriters have advised us that, pursuant to Regulation M of the Exchange Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.
These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on the NYSE, in the over-the-counter market or otherwise.
Selling restrictions
General
Other than in the United States, no action has been taken by us, the selling stockholders or the underwriters that would permit a public offering of the securities offered by this prospectus supplement and accompanying prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement and accompanying prospectus may not be offered or sold, directly or indirectly, nor may this prospectus supplement and accompanying prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement and accompanying prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this
 
S-21

Table of Contents
 
prospectus supplement and accompanying prospectus. This prospectus supplement and accompanying prospectus do not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement and accompanying prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.
Notice to prospective investors in the European Economic Area
In relation to each Member State of the European Economic Area (each, a “Relevant State”), no shares of our common stock have been offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of our common stock which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares of our common stock may be offered to the public in that Relevant State at any time: (a) to any qualified investor as defined under Article 2 of the Prospectus Regulation; (b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or (c) in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of the shares of our common stock shall require us, the selling stockholders or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation, supplement a prospectus pursuant to Article 23 of the Prospectus Regulation or publish an Annex IX document pursuant to Article 1(4) of the Prospectus Regulation.
For the purposes of this provision, the expression an “offer to the public” in relation to the shares of our common stock in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares of our common stock, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129, as amended.​
Notice to prospective investors in the United Kingdom
No shares of our common stock have been offered or will be offered pursuant to this offering to the public in the United Kingdom except that the shares of our common stock may be offered to the public in the United Kingdom at any time: (a) where (i) the offer is conditional on the admission of the shares of our common stock to trading on the London Stock Exchange plc’s main market (in reliance on the exception in paragraph 6(a) of Schedule 1 of the POATR) or (ii) the shares of our common stock being offered are at the time of the offer already admitted to trading on London Stock Exchange plc’s main market (in reliance on the exception in paragraph 6(b) of Schedule 1 of the POATR); (b) to any qualified investor as defined in paragraph 15 of Schedule 1 of the POATR; (c) to fewer than 150 persons (other than qualified investors as defined in paragraph 15 of Schedule 1 of the POATR), subject to obtaining the prior consent of the representatives for any such offer; or (d) in any other circumstances falling within Part 1 of Schedule 1 of the POATR.
For the purposes of this provision, the expression an “offer to the public” in relation to the shares of our common stock in the United Kingdom means the communication to any person which presents sufficient information on: (a) the shares of our common stock to be offered; and (b) the terms on which they are to be offered, to enable an investor to decide to buy or subscribe for the shares of our common stock and the expression “POATR” means the Public Offers and Admissions to Trading Regulations 2024.
The communication of this prospectus supplement, the accompanying prospectus and any other documents and/or materials relating to the shares of our common stock is not being made, and this prospectus supplement, the accompanying prospectus and such other documents and/or materials have not been approved, by an authorised person for the purposes of section 21 of the United Kingdom’s Financial Services and Markets Act 2000, as amended. This prospectus supplement, the accompanying prospectus and such other documents and/or materials are for distribution only to persons who: (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”); (ii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order; (iii) are outside
 
S-22

Table of Contents
 
the United Kingdom; or (iv) are any other persons to whom they may otherwise lawfully be communicated or distributed under the Financial Promotion Order (all such persons together being referred to as “relevant persons”). This prospectus supplement, the accompanying prospectus and such other documents and/or materials relating to the shares of our common stock are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this prospectus supplement, the accompanying prospectus and such other documents and/or materials relate is available only to relevant persons and will be engaged in only with relevant persons.
Notice to prospective investors in Canada
The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.
Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement or the accompanying prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.
Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.
Notice to prospective investors in Switzerland
This prospectus supplement and the accompanying prospectus do not constitute an offer to the public or a solicitation to purchase or invest in any shares. No shares have been offered or will be offered to the public in Switzerland, except that offers of shares may be made to the public in Switzerland at any time under the following exemptions under the Swiss Financial Services Act (“FinSA”):
(a) to any person which is a professional client as defined under the FinSA;
(b) to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to obtaining the prior consent of J.P. Morgan Securities LLC and Barclays Capital Inc., for any such offer; or
(c) in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss Financial Services Ordinance,
provided that no such offer of shares shall require us, the selling stockholders or any underwriter to publish a prospectus pursuant to Article 35 FinSA.
The shares have not been and will not be listed or admitted to trading on a trading venue in Switzerland.
Neither this document nor any other offering or marketing material relating to the shares constitutes a prospectus as such term is understood pursuant to the FinSA and neither this document nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in Switzerland.
Notice to prospective investors in the Dubai International Financial Centre (“DIFC”)
This document relates to an Exempt Offer in accordance with the Markets Law, DIFC Law No. 1 of 2012, as amended. This document is intended for distribution only to persons of a type specified in the Markets Law, DIFC Law No. 1 of 2012, as amended. It must not be delivered to, or relied on by, any other person. The Dubai
 
S-23

Table of Contents
 
Financial Services Authority (“DFSA”) has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement or the accompanying prospectus nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an authorized financial advisor.
In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.
Notice to prospective investors in the United Arab Emirates
The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus supplement and the accompanying prospectus do not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and are not intended to be a public offer. This prospectus supplement and the accompanying prospectus have not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority, the Financial Services Regulatory Authority (“FSRA”) or the Dubai Financial Services Authority.
Notice to prospective investors in Australia
This prospectus supplement and the accompanying prospectus:
•
do not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the “Corporations Act”);
​
•
have not been, and will not be, lodged with the Australian Securities and Investments Commission (“ASIC”), as a disclosure document for the purposes of the Corporations Act and do not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and
​
•
may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act (“Exempt Investors”).
​
The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor.
As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of sale of the shares, offer, transfer, assign or otherwise alienate those shares to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.
Notice to prospective investors in Japan
The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act.
 
S-24

Table of Contents
 
Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any “resident” of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time.
Notice to prospective investors in Hong Kong
The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “SFO”) of Hong Kong and any rules made thereunder; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the “CO”) or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the SFO and any rules made thereunder.
The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice.
Notice to prospective investors in Singapore
This prospectus supplement and the accompanying prospectus have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, no shares have been or will be offered or sold and no shares have been or will be made the subject of an invitation for subscription or purchase, and this prospectus supplement, the accompanying prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been and will not be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore, as modified or amended from time to time (the “SFA”)) pursuant to Section 274 of the SFA or (ii) to an accredited investor (as defined in Section 4A of the SFA) pursuant to and in accordance with the conditions specified in Section 275 of the SFA.
Notice to prospective investors in Bermuda
Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.
Notice to prospective investors in Saudi Arabia
This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on the Offer of Securities and Continuing Obligations Regulations as issued by the board of the Saudi Arabian Capital Market Authority (“CMA”) pursuant to resolution number 3-123-2017 dated 27 December 2017, as amended (the “CMA Regulations”). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser.
 
S-25

Table of Contents
 
Notice to prospective investors in the British Virgin Islands
The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of the Company. The shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (“BVI Companies”), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands.
Notice to prospective investors in China
This prospectus supplement and the accompanying prospectus will not be circulated or distributed in the People’s Republic of China (“PRC”) and the shares will not be offered or sold, and will not be offered or sold to any person for re-offering or resale directly or indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus supplement, the accompanying prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations.
Notice to prospective investors in Korea
The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder (the “FSCMA”), and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the “FETL”). The shares have not been listed on any securities exchange in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea.
Notice to prospective investors in Malaysia
No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with the Securities Commission of Malaysia (“Commission”) for the Commission’s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus supplement, the accompanying prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i) a closed end fund approved by the Commission; (ii) a holder of a Capital Markets Services Licence; (iii) a person who acquires the shares, as principal, if the offer is on terms that the shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv) an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3 million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v) an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi) an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii) a corporation with total net assets exceeding RM10 million (or its equivalent in foreign currencies) based on the last audited accounts; (viii) a partnership with total net assets exceeding RM10 million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi) any other person as may be specified by the Commission; provided that, in each of the preceding categories (i) to (xi), the distribution of the shares is made by a holder of
 
S-26

Table of Contents
 
a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus supplement and the accompanying prospectus is subject to Malaysian laws. This prospectus supplement and the accompanying prospectus do not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007.
Notice to prospective investors in Taiwan
The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitute an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan.
Notice to prospective investors in South Africa
Due to restrictions under the securities laws of South Africa, no “offer to the public” ​(as such term is defined in the South African Companies Act, No. 71 of 2008 (as amended or re-enacted) (the “South African Companies Act”)) is being made in connection with the issue of the shares in South Africa. Accordingly, this prospectus supplement and the accompanying prospectus do not, nor are they intended to, constitute a “registered prospectus” (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and have not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies:
​
Section 96(1) (a)
​ ​ the offer, transfer, sale, renunciation or delivery is to: ​
​ ​ ​ ​
(i)
persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;
​
​
​ ​ ​ ​
(ii)
the South African Public Investment Corporation;
​
​
​ ​ ​ ​
(iii)
persons or entities regulated by the Reserve Bank of South Africa;
​
​
​ ​ ​ ​
(iv)
authorised financial service providers under South African law;
​
​
​ ​ ​ ​
(v)
financial institutions recognised as such under South African law;
​
​
​ ​ ​ ​
(vi)
a wholly-owned subsidiary of any person or entity contemplated in (iii), (iv) or (v), acting as agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law);
​
​
​ ​ ​ ​
(vii)
any combination of the person in (i) to (vi); or
​
​
​ Section 96(1) (b) ​ ​ the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. ​
Information made available in this prospectus supplement and the accompanying prospectus should not be considered as “advice” as defined in the South African Financial Advisory and Intermediary Services Act, 2002.
Other relationships
The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and
 
S-27

Table of Contents
 
non-financial activities and services. Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. Certain of the underwriters or their respective affiliates act as lenders under our asset-based revolving credit facilities (the “ABL Facilities”) and/or our senior secured term loan facility (the “Term Loan B Facility”). An affiliate of BofA Securities, Inc. acts as the administrative agent and as a lender under our ABL Facilities and our Term Loan B Facility.
In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the Company (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with the Company. If the underwriters or their affiliates have a lending relationship with us, certain of those underwriters or their affiliates may hedge their credit exposure to us consistent with their customary risk management policies. Typically, the underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities, including potentially the shares of our common stock offered hereby. Any such credit default swaps or short positions could adversely affect future market prices of the shares of our common stock offered hereby. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.
 
S-28

Table of Contents​
 
LEGAL MATTERS
The validity of the shares of our common stock offered hereby will be passed upon for us by Stephen C. Petrovich, Executive Vice President, General Counsel and Secretary of Ardent Health, Inc. Certain other legal matters related to this offering will be passed upon for us and for EGI-AM Investments, L.L.C.by Sidley Austin LLP, New York, New York. Certain legal matters related to this offering will be passed upon for ALH Holdings, LLC by Davis Polk & Wardwell LLP, New York, New York. Certain legal matters related to this offering will be passed upon for the underwriters by Latham & Watkins LLP, New York, New York.
 
S-29

Table of Contents​
 
EXPERTS
The consolidated financial statements of Ardent Health, Inc. appearing in Ardent Health, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2025, and the effectiveness of Ardent Health, Inc.’s internal control over financial reporting as of December 31, 2025 have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.
 
S-30

Table of Contents​
 
WHERE YOU CAN FIND MORE INFORMATION
This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC and do not contain all of the information set forth in the registration statement and the exhibits thereto because some parts have been omitted in accordance with the rules and regulations of the SEC. You will find additional information about us and the common stock being sold in this offering in the registration statement and the exhibits thereto. For further information with respect to Ardent and the common stock being sold in this offering, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus supplement and the accompanying prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance, if such contract or document is filed as an exhibit, reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each statement being qualified in all respects by such reference. The SEC maintains an internet site (http://www.sec.gov), from which interested persons can electronically access the registration statement, including the exhibits and any schedules thereto.
We are subject to the informational requirements of the Exchange Act and, accordingly, file with the SEC annual reports containing financial statements audited by an independent registered public accounting firm, quarterly reports containing unaudited financial statements, current reports, proxy statements and other information. You can access these reports, proxy statements and other information without charge at the SEC’s website, which is listed above. You can also access, free of charge, our reports filed with the SEC (for example, our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K and any amendments to those forms) through our website (www.ardenthealth.com). Reports filed with or furnished to the SEC will be available as soon as reasonably practicable after they are filed with or furnished to the SEC. None of the information contained on, or that may be accessed through our website or any other website identified herein is part of, or incorporated into, this prospectus supplement, and you should not rely on any such information in connection with your decision to invest in our common stock. All website addresses in this prospectus supplement and the accompanying prospectus are intended to be inactive textual references only.
 
S-31

Table of Contents​
 
INCORPORATION BY REFERENCE
The SEC allows us to “incorporate by reference” into this prospectus supplement and the accompanying prospectus the information we file with the SEC in other documents. This means that we can disclose important information to you by referring to another document we have filed with the SEC. The information relating to us contained in this prospectus supplement and the accompanying prospectus should be read together with the information in the documents incorporated by reference.
We incorporate by reference, as of their respective dates of filing, the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act from the date of this prospectus supplement and until any offering of securities pursuant to this prospectus supplement and the accompanying prospectus is completed or otherwise terminated (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Exchange Act):
•
our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 16, 2026;
​
•
the portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 8, 2026 that are incorporated into Part III of our Annual Report on Form 10-K for the year ended December 31, 2025;
​
•
our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, filed with the SEC on May 6, 2026, August 10, 2026 and November 5, 2026, respectively;
​
•
our Current Reports on Form 8-K filed with the SEC on March 27, 2026, May 26, 2026, June 2, 2026 (solely with respect to Item 5.02), June 30, 2026, September 4, 2026 and October 23, 2026; and
​
•
the description of our common stock, which is registered under Section 12 of the Exchange Act, in our Form 8-A filed with the SEC on July 16, 2024, as updated by the description of our common stock set forth in Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025.
​
Any statement contained in a document that is incorporated by reference will be modified or superseded for all purposes to the extent that a statement contained in this prospectus supplement or the accompanying prospectus (or in any other document that is subsequently filed with the SEC and incorporated by reference) modifies or is contrary to that previous statement. Any statement so modified or superseded will not be deemed a part of this prospectus supplement and the accompanying prospectus except as so modified or superseded. In addition, upon request, we will provide to each person, including any beneficial owner, to whom a prospectus supplement and the accompanying prospectus is delivered, a copy of any or all of the reports or documents that have been incorporated by reference in this prospectus supplement or the accompanying prospectus contained in the registration statement, but not delivered with this prospectus supplement and the accompanying prospectus. You may request a copy of these filings (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost, by writing to or telephoning us at the following address or telephone number:
Ardent Health, Inc.
340 Seven Springs Way, Suite 100
Brentwood, Tennessee 37027
(615) 296-3000
Attention: Investor Relations
 
S-32

Table of Contents
PROSPECTUS
[MISSING IMAGE: lg_ardenthealth-4clr.jpg]
Ardent Health, Inc.
$500,000,000
Common stock
Preferred stock
Debt securities
120,453,642 Shares of our Common Stock
Offered by the Selling Stockholders
​
We may offer and sell, from time to time, shares of our common stock, shares of preferred stock, or debt securities, in any combination, together or separately, in one or more offerings in amounts, at prices and on terms that we determine at the time of the offering, with an aggregate offering price of up to $500 million. This prospectus describes the general manner in which those securities may be offered by us using this prospectus. We will specify in an accompanying prospectus supplement and any related free writing prospectus the particular terms of securities offered by us and the offering thereof and may also add, update or change information contained in this prospectus.
In addition, this prospectus relates to the offer and sale, from time to time, of up to 120,453,642 shares of our common stock (the “Selling Stockholder Shares”) by the selling stockholders identified in the “Selling Stockholders” section of this prospectus or their permitted transferees, pledgees, distributees, donees or other successors-in-interest (which we refer to collectively herein, together with such identified selling stockholders, as the “Selling Stockholders”). The Selling Stockholders may sell the shares of our common stock in a number of different ways and at varying prices. We provide more information about how the Selling Stockholders may sell the shares of our common stock in the section of this prospectus titled “Plan of Distribution—Selling Stockholders’ Plan of Distribution.” We will not receive any of the proceeds from the sale of our common stock by any of the Selling Stockholders. We have paid or will pay the fees and expenses incident to the registration of the shares of our common stock for sale by the Selling Stockholders. The Selling Stockholders will bear all discounts, commissions and stock transfer taxes, if any, attributable to their sales of the Selling Stockholder Shares.
You should read this prospectus, the information incorporated, or deemed to be incorporated, by reference in this prospectus, and any applicable prospectus supplement and related free writing prospectus carefully before you invest.
Our common stock is listed on the New York Stock Exchange under the symbol “ARDT.” On August 20, 2025, the last reported sales price for our common stock was $13.02 per share. None of the other securities we may offer are currently listed on any securities exchange. Any applicable prospectus supplement and any related free writing prospectus will contain information, where applicable, as to any other listing on the New York Stock Exchange or any securities market or exchange of the securities covered by the prospectus supplement and any related free writing prospectus.
​
An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading “Risk Factors” beginning on page 2 of this prospectus and, if applicable, any risk factors described in any accompanying prospectus supplement and in our Securities and Exchange Commission filings that are incorporated by reference into this prospectus before investing in our securities.
Common stock, preferred stock and/or debt securities may be sold by us, or common stock may be sold by the Selling Stockholders, to or through underwriters or dealers or directly to purchasers or through agents designated from time to time. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If any underwriters, dealers or agents are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, discounts or commissions, details regarding over-allotment options, if any, and the net proceeds to us will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is August 25, 2025

Table of Contents​
 
TABLE OF CONTENTS
​ ​ ​
Page
​
ABOUT THIS PROSPECTUS
​ ​ ​ ​ ii ​ ​
SUMMARY ​ ​ ​ ​ 1 ​ ​
RISK FACTORS
​ ​ ​ ​ 2 ​ ​
FORWARD-LOOKING STATEMENTS
​ ​ ​ ​ 3 ​ ​
WHERE YOU CAN FIND MORE INFORMATION
​ ​ ​ ​ 5 ​ ​
INFORMATION INCORPORATED BY REFERENCE
​ ​ ​ ​ 6 ​ ​
USE OF PROCEEDS
​ ​ ​ ​ 7 ​ ​
GENERAL DESCRIPTION OF SECURITIES
​ ​ ​ ​ 8 ​ ​
DESCRIPTION OF CAPITAL STOCK
​ ​ ​ ​ 9 ​ ​
DESCRIPTION OF DEBT SECURITIES
​ ​ ​ ​ 14 ​ ​
SELLING STOCKHOLDERS
​ ​ ​ ​ 26 ​ ​
PLAN OF DISTRIBUTION
​ ​ ​ ​ 28 ​ ​
LEGAL MATTERS
​ ​ ​ ​ 33 ​ ​
EXPERTS ​ ​ ​ ​ 33 ​ ​
 
i

Table of Contents​
 
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this shelf registration process, from time to time, we may sell any combination of the securities described in this prospectus in one or more offerings, in amounts, at prices and on terms that we determine at the time of the offering, with an aggregate offering price of up to $500 million, and the Selling Stockholders may sell up to 120,453,642 Selling Stockholder Shares from time to time in one or more offerings as described in this prospectus. We have provided to you in this prospectus a general description of the securities we may offer. Each time we sell securities under this shelf registration process, we will provide a prospectus supplement that will contain specific information about the terms of the offering. We, or the Selling Stockholders, may also add, update or change in any prospectus supplement any of the information contained in this prospectus. To the extent that there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement; provided that, if any statement in one of these documents is inconsistent with a statement in another document having a later date, then the statement in the document having the later date will modify or supersede the earlier statement. You should read both this prospectus and any prospectus supplement together with the additional information described under the heading “Where You Can Find More Information.”
Neither we, the Selling Stockholders nor any agent, underwriter or dealer has authorized anyone to give you any information or to make any representation other than the information and representations contained in or incorporated by reference into this prospectus or any applicable prospectus supplement or free writing prospectus. We, the Selling Stockholders and any agent, underwriter or dealer take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You may not imply from the delivery of this prospectus and any applicable prospectus supplement or any free writing prospectus, nor from a sale made under this prospectus and any applicable prospectus supplement or any free writing prospectus, that our affairs have remained unchanged since the date of this prospectus and any applicable prospectus supplement or free writing prospectus or that the information contained in any document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this prospectus and any applicable prospectus supplement or any free writing prospectus or any sale of a security. This prospectus and any applicable prospectus supplement may only be used where it is legal to sell the securities.
In this prospectus, unless the context otherwise requires, the terms “Ardent,” “the Company,” “we,” “us,” and “our” refer to Ardent Health, Inc. and direct and indirect subsidiaries of Ardent Health, Inc. and partnerships and joint ventures in which such subsidiaries are equity owners on a consolidated basis.
 
ii

Table of Contents​
 
SUMMARY
This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider when making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, as well as under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our consolidated financial statements, and the exhibits to the registration statement of which this prospectus forms a part.
Company overview
We are a leading provider of healthcare services in the United States, operating in eight growing mid-sized urban markets across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas. We deliver care through a system of 30 acute care hospitals and approximately 280 sites of care with 1,875 employed and affiliated providers as of June 30, 2025. Affiliated providers are physicians and advanced practice providers with whom we contract for services through a professional services agreement or other independent contractor agreement. We hold a leading position in a majority of our markets, and we believe we are one of the leading healthcare systems based on market share and our integrated network of hospitals, ambulatory facilities, and physician practices. We operate either independently or in partnership with premier academic medical centers, large not-for-profit hospital systems, community physicians, and a community foundation through our well-established and differentiated joint venture (“JV”) model. Collectively, we operate with a consumer-centric approach to caring for our patients and our communities. Our strategic JV partners offer us significant advantages, including expanded access points, clinical talent availability, local brand recognition, and scale that enable us to accelerate market penetration. We believe that we help our partners enhance their network and regional presence through our operational acumen. We strive to strengthen clinical services, drive operating improvements, and centrally manage operations to optimize hospital performance and enhance patient care. In each of these partnerships, we are the majority owner and serve as the day-to-day operator.
As of August 4, 2025, EGI-AM Investments, L.L.C. (“EGI-AM”) owned approximately 54.0% of our outstanding common stock. As a result, EGI-AM is our controlling stockholder and we are a “controlled company” within the meaning of the corporate governance standards of the New York Stock Exchange. EGI-AM is an affiliated entity of Equity Group Investments, a private investment firm founded more than 50 years ago by Sam Zell.
Corporate information
Ardent Health, Inc. was initially formed in 2015 as a Delaware limited liability company. On July 17, 2024, Ardent Health Partners, LLC converted from a Delaware limited liability company into a Delaware corporation in connection with its initial public offering and changed its name to Ardent Health Partners, Inc. Effective June 3, 2025, Ardent Health Partners, Inc. changed its name to Ardent Health, Inc. Ardent Health, Inc. is a holding company that has affiliates that operate acute care hospitals and other healthcare facilities and employ physicians.
Our principal executive offices are located at 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027, and our telephone number is (615) 296-3000. Our website address is www.ardenthealth.com, and the information contained on, or accessible from, or hyperlinked to, our website and our facilities’ websites is not part of this prospectus by reference or otherwise.
 
1

Table of Contents​
 
Risk factors
An investment in our securities involves a high degree of risk. Please see the risk factors described in Item 1A “Risk Factors” in our most recent Annual Report on Form 10-K, which is incorporated by reference in this prospectus, as well as any risk factors included in any other filings we have made with the SEC that are incorporated by reference herein or set forth in any applicable prospectus supplement that accompanies this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations, results of operations or financial condition. Additional risk factors may be included in an applicable prospectus supplement relating to a particular offering of our securities. These risks could materially affect our business operations, results of operations or financial condition. You could lose all or part of your investment.
 
2

Table of Contents​
 
FORWARD-LOOKING STATEMENTS
This prospectus and documents incorporated by reference herein contain “forward-looking statements,” as that term is defined in the U.S. federal securities laws. These forward-looking statements include, but are not limited to, statements other than statements of historical facts, including, among others, statements relating to our future financial performance, our business prospects and strategy, anticipated financial position, liquidity and capital needs, the industry in which we operate and other similar matters. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements. Factors, risks, and uncertainties that could cause actual outcomes and results to be materially different from those contemplated include, among others: (1) general economic and business conditions, both nationally and in the regions in which we operate, including the impact of challenging macroeconomic conditions and inflationary pressures, current geopolitical instability, and impacts from the imposition of, or changes in, tariffs, as well as the potential impact on us of uncertain political, financial, credit and capital conditions; (2) possible reductions or other changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs or state directed payments, that could have an adverse effect on our revenues and business; (3) reduction in the reimbursement rates paid by commercial payors, increased reimbursement denials or payment delays by commercial payors, our inability to retain and negotiate favorable contracts with private third party payors, or an increasing volume of uninsured or underinsured patients; (4) effects of changes in healthcare policy or legislation, including the One Big Beautiful Bill Act (the “OBBBA”) and any other reforms that have or may be undertaken by the current presidential administration, and legal and regulatory restrictions on our hospitals that have physician owners; (5) the ability to achieve operating and financial targets, develop and execute mitigation plans to offset to the extent possible impacts from the OBBBA, the scheduled expiration of temporary enhanced subsidies for individuals eligible to purchase insurance coverage through health insurance marketplaces and imposition of tariffs, attain expected levels of patient volumes and revenues, and control the costs of providing services; (6) security threats, catastrophic events and other disruptions affecting our, our service providers’ or our JV partners’ information technology and related systems, which have adversely affected, and could in the future adversely affect, our relationships with patients and business partners and subject us to legal claims and liabilities, reputational harm and business disruption and adversely affect our financial condition; (7) the highly competitive nature of the healthcare industry and continued industry trends towards clinical transparency and value-based purchasing may impact our competitive position; (8) inability to recruit and retain quality physicians, as well as increasing cost to contract with hospital-based physicians; (9) changes to physician utilization practices and treatment methodologies and other factors outside our control that impact demand for medical services and may reduce our revenues and ability to grow profitability; (10) the effects related to the sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential for future deficit reduction legislation; (11) continued industry trends toward value-based purchasing, third party payor consolidation and care coordination among healthcare providers; (12) inability to successfully complete acquisitions or strategic JVs or inability to realize all of the anticipated benefits; (13) liabilities because of professional liability and other claims brought against our hospitals, physician practices, outpatient facilities or other business operations; (14) exposure to certain risks and uncertainties by the JVs through which we conduct a significant portion of our operations, including anticipated synergies, of past acquisitions and the risk that transactions may not receive necessary government clearances; (15) failure to obtain drugs and medical supplies at favorable prices or sufficient volumes; (16) operational, legal and financial risks associated with outsourcing functions to third parties; (17) our facilities are heavily concentrated in Texas and Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states; (18) negative impact of severe weather, climate change, and other factors beyond our control, which could restrict patient access to care or cause one or more facilities to close temporarily or permanently; (19) risks related to the master lease agreement with subsidiaries of Ventas, Inc. (“Ventas”), pursuant to which we lease ten of our hospitals, and its restrictions and limitations on our business; (20) the impact of our significant indebtedness and the ability to refinance such indebtedness on
 
3

Table of Contents
 
acceptable terms; (21) our failure to comply with complex laws and regulations applicable to the healthcare industry or to adjust our operations in response to changing laws and regulations; (22) the impact of governmental claims or governmental investigations, payor audits and litigation brought against our hospitals, physician practices, outpatient facilities or other business operations; (23) actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements; (24) the impact of a deterioration of public health conditions associated with a future pandemic, epidemic or outbreak of infectious disease; (25) inability to or delay in building, acquiring, selling, renovating or expanding our healthcare facilities; (26) failure to comply with federal and state laws relating to Medicare and Medicaid enrollment, permit, licensing and accreditation requirements; (27) the results of our efforts to use technology, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience; (28) our status as a controlled company; (29) conflicts of interest between our controlling stockholder and other holders of our common stock; and (30) other risk factors described in our filings with the SEC, including those discussed in Item 1A “Risk Factors” in our most recent Annual Report on Form 10-K, as well as those discussed in this prospectus, the documents incorporated by reference into this prospectus or any free writing prospectus.
We caution you that the foregoing list may not contain all of the risks and uncertainties that may affect the forward-looking statements made in this prospectus. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements in this prospectus are based on our management’s current beliefs, expectations, and projections about future events and trends affecting our business, results of operations, financial condition, and prospects. These statements are subject to risks, uncertainties, and other factors described in the “Risk Factors” section and included our filings with the SEC. We operate in a competitive and rapidly changing environment where new risks and uncertainties can emerge, making it impossible to predict all potential impacts on our forward-looking statements. Consequently, actual results may differ materially from those described. The forward-looking statements pertain only to the date they are made, and we do not undertake any obligation to update them to reflect new information or events unless required by law. You are advised not to place undue reliance on these statements and to consult any additional disclosures we may provide through the documents incorporated by reference into this prospectus, any free writing prospectus and our other filings with the SEC, such as our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
 
4

Table of Contents​
 
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. The SEC’s website can be found at www.sec.gov. Our SEC filings are available free of charge on the “Investor Relations” page of our website at www.ardenthealth.com as soon as reasonably practicable after we electronically file these materials with the SEC. You may access these SEC filings on our website. Except for those SEC filings expressly incorporated by reference in this prospectus or any applicable prospectus supplement, none of the other information on our website is part of this prospectus or incorporated by reference into this prospectus or any applicable prospectus supplement.
This prospectus is part of a registration statement filed on Form S-3 with the SEC under the Securities Act, and the rules and regulations promulgated by the SEC thereunder. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information concerning us and our securities, you should read the entire registration statement and the additional information described below. The registration statement has been filed electronically and may be obtained in any manner listed above. Any statements contained herein concerning the provisions of any document are not necessarily complete, and, in each instance, reference is made to the copy of such document filed as an exhibit to the registration statement or otherwise filed with the SEC. Each such statement is qualified in its entirety by such reference.
 
5

Table of Contents​
 
INFORMATION INCORPORATED BY REFERENCE
The rules of the SEC allow us to “incorporate by reference” information in this prospectus, which means that we can disclose important information to you by referring to those documents we file with the SEC. Any information incorporated this way is considered to be part of this prospectus, and any information that we file later with the SEC will automatically update and, in some cases, supersede the information contained or incorporated by reference herein. We hereby “incorporate by reference” the documents and information listed below (other than, in each case, documents or information deemed to be furnished and not filed in accordance with SEC rules):
•
Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025;
​
•
the information contained in our definitive proxy statement on Schedule 14A for our 2025 annual meeting of stockholders filed with the SEC on April 8, 2025, to the extent incorporated by reference in Part III of our Annual Report on Form 10-K for the year ended December 31, 2024;
​
•
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on May 7, 2025 and August 6, 2025, respectively;
​
•
Current Reports on Form 8-K filed with the SEC on January 13, 2025 (solely with respect to Item 5.02), March 31, 2025, April 3, 2025, May 23, 2025 and June 20, 2025; and
​
•
the description of our common stock, which is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in our Form 8-A filed with the SEC on July 16, 2024, as updated by the description of our common stock set forth in Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025.
​
All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement, shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents.
Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or any applicable prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement.
Upon your oral or written request, we will provide you with a copy of any of these filings at no cost. Requests should be directed to:
Ardent Health, Inc.
340 Seven Springs Way, Suite 100
Brentwood, Tennessee 37027
(615) 296-3000
Attention: Investor Relations
Exhibits to any documents incorporated by reference in this prospectus will not be sent, however, unless those exhibits have been specifically referenced in this prospectus.
 
6

Table of Contents​
 
USE OF PROCEEDS
Unless otherwise stated in any applicable prospectus supplement, we will use the net proceeds from the sale of any securities that may be offered by us for working capital, to acquire complementary businesses, products, services or technologies and for general corporate purposes, which may include repayment of debt and capital expenditures. Pending such use, any net proceeds may be invested temporarily in short-term, interest-bearing, investment-grade securities and/or similar assets as we may determine.
We will not receive any of the proceeds from the sale of common stock being offered by any of the Selling Stockholders.
 
7

Table of Contents​
 
GENERAL DESCRIPTION OF SECURITIES
We may offer and sell, at any time and from time to time:
•
shares of our common stock, par value $0.01 per share;
​
•
shares of our preferred stock, par value $0.01 per share;
​
•
our debt securities in one or more series, in each case consisting of notes or other unsecured evidences of indebtedness; or
​
•
any combination of the foregoing securities.
​
The Selling Stockholders may also offer and sell shares of our common stock from time to time in connection with this offering.
The terms of any securities offered will be determined at the time of sale. We may issue debt securities that are exchangeable for and/or convertible into common stock or any of the other securities that may be sold under this prospectus. When particular securities are offered, a prospectus supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering and sale of the offered securities. To the extent the information contained in any applicable prospectus supplement differs from the general description set forth in this prospectus, you should rely on the information in that prospectus supplement.
 
8

Table of Contents​
 
DESCRIPTION OF CAPITAL STOCK
We have provided below a summary description of our capital stock. This description does not purport to be complete and is qualified in its entirety by reference to the full text of our certificate of incorporation, as amended (our “Certificate of Incorporation”), and our amended and restated bylaws (our “Bylaws”), each of which is filed as an exhibit to the registration statement of which this prospectus forms a part and incorporated by reference herein, and to the applicable provisions of the General Corporation Law of the State of Delaware, which we refer to as the “DGCL.” To find out where copies of our Certificate of Incorporation and Bylaws can be obtained, see “Where You Can Find More Information.” References in this “Description of Capital Stock” section to “the Company,” “we,” “us,” “our” and “ours” refer to Ardent Health, Inc. and not to any of its subsidiaries.
General
Under our Certificate of Incorporation, we have authority to issue (i) 750,000,000 shares of our common stock, par value $0.01 per share, and (ii) 50,000,000 shares of preferred stock, par value $0.01 per share. As of August 4, 2025, we had 143,106,447 shares of our common stock issued and outstanding and no shares of preferred stock issued and outstanding.
Common stock
Our ability to pay dividends on our common stock is subject to our subsidiaries’ ability to pay dividends to us, which is, in turn, subject to the restrictions set forth in our existing debt agreements and which may be limited by the agreements governing other indebtedness we or our subsidiaries incur in the future.
The holders of our common stock do not have any preemptive, cumulative voting, subscription, conversion, redemption or sinking fund rights. Our common stock is not subject to future calls or assessments by us. The rights and privileges of the holders of our common stock are subject to any series of preferred stock that we may issue in the future.
Preferred stock
No shares of our authorized preferred stock are currently outstanding. Under our Certificate of Incorporation, our Board of Directors (the “Board”) has the authority, without further action by our stockholders, to issue up to 50 million shares of preferred stock in one or more series and to fix the voting powers, designations, preferences and the relative participating, optional or other special rights and qualifications, limitations and restrictions of each series, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any series. Because the Board has the power to establish the preferences and rights of the shares of any series of preferred stock, it may afford holders of any preferred stock preferences, powers and rights, including voting and dividend rights, senior to the rights of holders of our common stock, which could adversely affect the holders of our common stock and could delay, discourage or prevent a takeover of us even if a change of control of our Company would be beneficial to the interests of our stockholders.
Voting rights
Each holder of our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 662∕3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our Certificate of Incorporation, such as the provisions relating to amending our Bylaws and director liability.
Dividend rights
Holders of our common stock are entitled to receive, on a pro rata basis, dividends, if any, as may be declared from time to time by our Board out of legally available funds, subject to preference that may be applicable to
 
9

Table of Contents
 
preferred stock, if any, then outstanding. Although we have paid cash dividends to our equity holders in the past, we currently do not expect to pay dividends on shares of our common stock and we currently intend to retain all available funds and any future earnings for use in the operation of our business. Any future determination to pay dividends will be made at the discretion of our Board and will depend on many factors, including our financial condition, earnings, legal and regulatory requirements, restrictions in our debt agreements and other factors our Board deems relevant.
Liquidation rights
In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share equally and ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights, if any, of holders of any outstanding shares of preferred stock.
Rights and preferences
Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock.
Fully paid and nonassessable
All of our outstanding common stock is fully paid and nonassessable.
Registration rights
Pursuant to the Registration Rights Agreement, dated as of July 3, 2015, and as amended on May 1, 2023 (as so amended, the “Registration Rights Agreement”), EGI-AM, ALH Holdings, LLC, a subsidiary of Ventas, Pure Health Capital Americas 1 SPV RSC LTD (“Pure Health”) and certain current and former executive officers of the Company are entitled to rights with respect to the registration of their shares under the Securities Act. The Registration Rights Agreement provides for customary demand and piggyback registration rights. Under the Registration Rights Agreement, the stockholders party thereto, or their permitted transferees, have the right to require us to register their shares under the Securities Act, so that those shares may be publicly resold, and such stockholders, or their permitted transferees, have the right to include their shares in any registration statement we file.
Anti-takeover effects of provisions of our Certificate of Incorporation, Bylaws and Delaware Law
Some provisions of the DGCL and our Certificate of Incorporation and our Bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.
These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Delaware anti-takeover statute
Our Certificate of Incorporation provides that we are not governed by Section 203 of the DGCL which, in the absence of such provisions, would have imposed additional requirements regarding mergers and other business combinations.
 
10

Table of Contents
 
However, our Certificate of Incorporation includes a provision that restricts us from engaging in any business combination with an interested stockholder for three years following the date that person becomes an interested stockholder. Such restrictions shall not apply to any business combination between EGI-AM and any affiliate thereof or their direct and indirect transferees, on the one hand, and us, on the other.
Additionally, we would be able to enter into a business combination with an interested stockholder if:
•
before that person became an interested stockholder, our Board approved the transaction in which the interested stockholder became an interested stockholder or approved the business combination;
​
•
upon the consummation of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) stock held by directors who are also officers of our Company and by employee stock plans that do not provide employees with the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or
​
•
following the transaction in which that person became an interested stockholder, the business combination is approved by our Board and authorized at a meeting of stockholders by the affirmative vote of the holders of at least 662∕3% of our outstanding voting stock not owned by the interested stockholder.
​
In general, a “business combination” is defined to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder and an “interested stockholder” is any person who, together with affiliates and associates, is the owner of 15% or more of our outstanding voting stock or is our affiliate or associate and was the owner of 15% or more of our outstanding voting stock at any time within the three-year period immediately before the date of determination. Under our Certificate of Incorporation, an “interested stockholder” does not include EGI-AM and any affiliate thereof or their direct and indirect transferees.
This provision of our Certificate of Incorporation could prohibit or delay mergers or other takeovers or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.
Board vacancies
Our Certificate of Incorporation and Bylaws provide that only our Board will be allowed to fill vacant directorships.
Special stockholder meetings
Our Bylaws provide that a special meeting of stockholders may be called by our Board, or by our President or Chief Executive Officer. Our Bylaws prohibit any stockholder from calling a special meeting of stockholders.
Requirements for advance notification of stockholder nominations and proposals
Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the Board or a committee of the Board.
Elimination of stockholder action by written consent
Our Certificate of Incorporation and our Bylaws eliminate the right of stockholders to act by written consent without a meeting.
Choice of forum
Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of a fiduciary duty owed by any
 
11

Table of Contents
 
current or former director, officer or other employee to us or our stockholders; any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws; any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine; or any other action asserting an internal corporate claim, in all cases subject to the court’s having personal jurisdiction over all indispensable parties named as defendants. Similarly, our Certificate of Incorporation provides that the U.S. federal district courts are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. Although our Certificate of Incorporation contains the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.
Amendment of charter provisions
The amendment of any of the above provisions would require approval by a stockholder vote by the holders of at least a majority of the voting power of the then outstanding voting stock. In addition, our directors are expressly authorized to amend our Bylaws without the approval of our stockholders.
The provisions of the DGCL, our Certificate of Incorporation and our Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
Limitation of liability and indemnification
Our Certificate of Incorporation limits the liability of our directors and officers to the maximum extent permitted by the DGCL. The DGCL provides that directors and officers will not be personally liable for monetary damages for breach of fiduciary duty as directors or officers, except liability:
•
for any breach of their duty of loyalty to the corporation or its stockholders;
​
•
for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
​
•
under Section 174 of the DGCL (governing distributions to stockholders);
​
•
for any transaction from which the director derived an improper personal benefit; or
​
•
for any action by or in the right of the corporation.
​
However, if the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors and officers, then the liability of our directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. The modification or repeal of this provision of our Certificate of Incorporation will not adversely affect any right or protection of a director or officer existing at the time of such modification or repeal.
Our Certificate of Incorporation provides that we will, to the fullest extent from time to time permitted by law, indemnify our directors and officers against all liabilities and expenses in any proceeding, arising out of their status as an officer or director or their activities in these capacities. We will also indemnify any person who, at our request, is or was serving as a director, officer, employee or agent of another corporation, partnership, JV, trust or other enterprise. We may, by action of our Board, provide indemnification to our employees and agents within the same scope and effect as the foregoing indemnification of directors and officers.
The right to be indemnified will include the right of an officer or a director to be paid expenses in advance of the final disposition of any proceeding, provided that, if required by law, we receive a written undertaking to repay such amount if it will be determined that he or she is not entitled to be indemnified.
 
12

Table of Contents
 
Our Board may take such action as it deems necessary to carry out these indemnification provisions, including adopting procedures for determining and enforcing indemnification rights and purchasing insurance policies. Our Board may also adopt bylaws, resolutions or contracts implementing indemnification arrangements as may be permitted by law. Neither the amendment, repeal or modification of these indemnification provisions, nor any provision of our Certificate of Incorporation that is inconsistent with these indemnification provisions, will eliminate or reduce any rights to indemnification relating to their status or any activities prior to such amendment, repeal or modification.
We believe these provisions will assist in attracting and retaining qualified individuals to serve as directors.
Corporate opportunities
Under Delaware law, officers and directors generally have an obligation to present to the corporation they serve business opportunities which the corporation is financially able to undertake and which falls within the corporation’s business line and are of practical advantage to the corporation, or in which the corporation has an actual or expectant interest. A corollary of this general rule is that when a business opportunity comes to an officer or director that is not one in which the corporation has an actual or expectant interest, the officer is generally not obligated to present it to the corporation. Certain of our officers and directors may serve as officers, directors or fiduciaries of other entities and, therefore, may have legal obligations relating to presenting available business opportunities to us and to other entities. Potential conflicts of interest may arise when our officers and directors learn of business opportunities (e.g., the opportunity to acquire an asset or portfolio of assets, to make a specific investment, to effect a sale transaction, etc.) that would be of material advantage to us and to one or more other entities of which they serve as officers, directors or other fiduciaries.
Section 122(17) of the DGCL permits a corporation to renounce, in advance, in its certificate of incorporation or by action of its board of directors, any interest or expectancy of a corporation in certain classes or categories of business opportunities. Where business opportunities are so renounced, certain of our officers and directors will not be obligated to present any such business opportunities to us. Our Certificate of Incorporation provides that, to the fullest extent permitted by law, no officer or director of ours who is also an officer, director, employee, managing director or other affiliate of EGI-AM or ALH Holdings, LLC (a subsidiary of Ventas) or any of their respective affiliates will be liable to us or our stockholders for breach of any fiduciary duty by reason of the fact that any such individual directs a corporate opportunity to EGI-AM or Ventas or any of their respective affiliates instead of us, or does not communicate information regarding a corporate opportunity to us that the officer, director, employee, managing director or other affiliate has directed to EGI-AM or Ventas or any of their respective affiliates (other than us), as applicable. This provision of our Certificate of Incorporation relates only to the EGI-AM and Ventas designees to our Board, namely Messrs. Sen and Sotir and Mses. Campion and Havdala (in the case of EGI-AM) and Mr. Bulgarelli (in the case of Ventas).
Listing
Our common stock is listed on the New York Stock Exchange under the symbol “ARDT.”
Nomination agreement
On July 19, 2024, we entered into a Nomination Agreement with EGI-AM and ALH Holdings, LLC (a subsidiary of Ventas) that provides certain Board nomination and committee designation rights for EGI-AM and certain Board nomination rights for ALH Holdings, LLC. For additional information, see “Certain Relationships and Related Party Transactions—Nomination Agreement” in our definitive proxy statement on Schedule 14A, filed with the SEC on April 8, 2025, which is incorporated by reference herein.
Transfer agent and registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.
 
13

Table of Contents​
 
DESCRIPTION OF DEBT SECURITIES
The following is a general description of the terms and provisions of debt securities we may issue from time to time pursuant to this prospectus unless we provide otherwise in the applicable prospectus supplement. In this “Description of Debt Securities” section, unless specifically noted otherwise or unless the context otherwise requires, all references to “the Issuer,” “we,” “us,” “our” and “ours” refer to Ardent Health, Inc., as issuer of the debt securities, and not to any of the Issuer’s subsidiaries.
As required by federal law for all bonds and notes of companies that are publicly offered, any debt securities we issue will be governed by a document called an “indenture.” We have summarized the general features of the debt securities to be governed by the indenture. The summary is not complete. An indenture is a contract between us and a financial institution acting as trustee on behalf of the holders of the debt securities and is subject to and governed by the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”). The trustee has two main roles. First, the trustee can enforce holders’ rights against us if we default. There are some limitations on the extent to which the trustee acts on holders’ behalf, described under “—Events of Default, Notice and Waiver.” Second, the trustee performs certain administrative duties, such as sending interest and principal payments to holders.
Because this section is a summary, it does not describe every aspect of any debt securities we may issue or the indenture governing any such debt securities. The statements made hereunder relating to any indenture and the debt securities to be issued thereunder are summaries and do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all anticipated provisions of the indentures and the debt securities.
General
The indenture may provide that the debt securities may be issued without limit as to aggregate principal amount, in one or more series. All debt securities of one series need not be issued at the same time and, unless otherwise provided, a series of debt securities may be reopened, without notice to, or the consent of, the holders of the debt securities of such series, for issuances of additional debt securities of such series or to establish additional terms of such series.
The indenture may provide that there may be more than one trustee thereunder, each with respect to one or more series of debt securities. Any trustee under the indenture may resign as to the debt securities of one or more series or be removed as to the debt securities of any series by the holders of a majority in principal amount of the debt securities of such series then outstanding or, under certain circumstances, by the Issuer, and a successor trustee may be appointed to act with respect to such series. In the event that two or more persons are acting as trustee with respect to different series of debt securities, each trustee shall be a trustee of a trust under the indenture separate and apart from the trust administered by any other trustee, and, unless otherwise indicated herein, any action described herein to be taken by the trustee may be taken by each trustee with respect to, and only with respect to, the debt securities of the series for which it is trustee under the indenture.
For a detailed description of the debt securities of any series, you should consult the applicable prospectus supplement relating to debt securities. Prior to the issuance of debt securities of any series, the following terms shall be established in, or pursuant to, authority granted by a resolution of the Issuer’s Board and set forth in an officers’ certificate, or established in one or more of indentures supplemental to the indenture:
(1) the title of such debt securities;
(2) any limit upon the aggregate principal amount of such debt securities which may be authenticated and delivered under the indenture (except as otherwise permitted under the indenture);
(3) if any of such debt securities are to be issuable in global form, when any of such debt securities are to be issuable in global form and (i) whether such debt securities are to be issued in temporary or
 
14

Table of Contents
 
permanent global form or both, (ii) whether beneficial owners of interests in any such global security may exchange such interests for debt securities of the same series and of like tenor and of any authorized form and denomination, and the circumstances under which any such exchanges may occur, if other than in the manner specified in the indenture, (iii) the name of the depository with respect to any such global security and (iv) if applicable and in addition to the persons specified in the indenture, the person or persons who shall be entitled to make any endorsements on any such global security and to give the instructions and take the other actions with respect to such global security contemplated in the indenture;
(4) the date or dates, or the method or methods, if any, by which such date or dates shall be determined, on which the principal of, and any premium on, such debt securities will be payable;
(5) the rate or rates at which such debt securities shall bear interest, if any, or the method or methods, if any, by which such rate or rates are to be determined, the date or dates, if any, from which such interest shall accrue or the method or methods, if any, by which such date or dates are to be determined, the interest payment dates, if any, on which such interest shall be payable and the regular record date, if any, for the interest payable on such debt securities on any interest payment date, the notice, if any, to holders regarding the determination of interest on a floating rate security and the manner of giving such notice, and the basis upon which interest shall be calculated if other than that of a 360-day year of twelve 30-day months;
(6) if in addition to or other than the corporate trust office of the trustee, the place or places where the principal of, or any premium and interest on, such debt securities shall be payable, any of such debt securities may be surrendered for registration of transfer or exchange and notices or demands to or upon the Issuer in respect of such debt securities and the indenture may be served;
(7) whether any of such debt securities are to be redeemable at the option of the Issuer and, if so, the date or dates on which, the period or periods within which, the price or prices at which, and the other terms and conditions upon which, such debt securities may be redeemed, in whole or in part, at the option of the Issuer;
(8) if the Issuer is obligated to redeem or repay any of such debt securities pursuant to any sinking fund or analogous provision or at the option of any holder thereof, or otherwise, and, if so, the date or dates on which, the period or periods within which, the price or prices at which, and the other terms and conditions upon which such debt securities shall be redeemed or repaid, in whole or in part, pursuant to such obligation, and any provisions for the remarketing of such debt securities so redeemed or purchased;
(9) the denominations in which any of such debt securities shall be issuable if other than minimum denominations of $2,000 and any integral multiple of $1,000 in excess thereof;
(10) whether such debt securities will be convertible into, and/or exchangeable for, any securities or other property and, if so, the terms and conditions upon which such debt securities will be so convertible and/or exchangeable, and any deletions from or modifications of or additions to the indenture to permit or to facilitate the issuance of such convertible and/or exchangeable debt securities or the administration thereof;
(11) if other than the principal amount thereof, the portion of the principal amount of any of such debt securities that shall be due and payable upon acceleration of the maturity thereof, or the method by which such portion is to be determined;
(12) if other than U.S. dollars, the foreign currency in which purchases of such debt securities must be made and the foreign currency in which payment of the principal of, and any premium or interest on, such debt securities shall be payable;
(13) if the principal of, or any premium or interest on, such debt securities are to be payable, at the election of the Issuer or a holder thereof or otherwise, in a currency other than that in which such debt securities are stated to be payable, the date or dates on which, the period or periods within which, and the other terms and conditions upon which, such determination may or shall be made, and the time and manner of determining the exchange rate between the currency in which such debt securities are stated to be payable and the currency in which such debt securities or any of them are to be paid pursuant to such determination, and any deletions from or
 
15

Table of Contents
 
modifications of or additions to the terms of the indenture to provide for or to facilitate the issuance of debt securities denominated or payable, at the election of the Issuer or a holder thereof or otherwise, in a foreign currency;
(14) if the amount of payments of principal of, or any premium or interest on, such debt securities may be determined with reference to an index, formula or other method or methods (which index, formula or method or methods may be based, without limitation, on one or more currencies, commodities, equity indices or other indices), and, if so, the terms and conditions upon which, and the manner in which, such amounts shall be determined and paid or payable;
(15) any deletions from, modifications of or additions to the events of default or covenants of the Issuer with respect to any of such debt securities (whether or not such events of default or covenants are consistent with the events of default or covenants described herein);
(16) if (i) any one or more of the indenture provisions relating to satisfaction and discharge or legal defeasance shall not be applicable to such debt securities, (ii) there shall be covenants of the Issuer that shall be subject to covenant defeasance and, if so, which such covenants, (iii) such debt securities are subject to repayment at the option of the holders thereof, whether the Issuer’s obligation to repay such debt securities will be subject to satisfaction and discharge, legal defeasance and/or covenant defeasance under the indenture, and(iv) the holders of such debt securities have the right to convert and/or exchange such debt securities into any securities or other property, whether the right to effect such conversion and/or exchange will be subject to satisfaction and discharge, legal defeasance and/or covenant defeasance under the indenture, and any deletions from, or modifications of or additions to the satisfaction and discharge, legal defeasance and/or covenant defeasance provisions of the indenture (including any modification which would permit satisfaction and discharge, legal defeasance and/or covenant defeasance to be effected with respect to less than all of the outstanding debt securities of such series) in respect of such debt securities;
(17) if any of such debt securities are to be issuable upon the exercise of warrants, and the time, manner and place for such debt securities to be authenticated and delivered;
(18) if any of such debt securities are issuable in global form and are to be issuable in definitive form (whether upon original issuance or upon exchange of a temporary debt security) only upon receipt of certain certificates or other documents or satisfaction of other conditions, then the form and terms of such certificates, documents or conditions;
(19) the circumstances under which the Issuer will pay additional amounts in respect of such debt securities with respect to any tax, assessment or other government charge and whether the Issuer will have the option to redeem such debt securities rather than trigger the requirement for the payment of such additional amounts;
(20) if there is more than one trustee, the identity of the trustee that has any obligations, duties and remedies with respect to such debt securities and, if not the trustee, the identity of each security registrar, paying agent or authenticating agent with respect to such debt securities;
(21) the person to whom any interest on such debt securities shall be payable, if other than the person in whose name any such debt security (or one or more predecessor securities) is registered at the close of business on the regular record date for such interest, the manner in which, or the person to whom, and the extent to which, or the manner in which, any interest payable on a temporary global security will be paid if other than in the manner provided in the indenture;
(22) if such debt securities shall constitute subordinated indebtedness and, if so, the definition of senior indebtedness and the applicability of other subordination provisions relating thereto, and any deletions from or modifications of or additions to the indenture to permit or to facilitate the issuance of such subordinated debt securities or the administration thereof; and
(23) any other terms of such debt securities and any deletions from or modifications of or additions to the indenture in respect of such debt securities.
 
16

Table of Contents
 
Except as described herein under “—Merger, Consolidation or Sale,” or as otherwise described in the applicable prospectus supplement relating to the debt securities of any series, an indenture will not contain any other provisions that would limit the ability of the Issuer and its subsidiaries to incur indebtedness or to substantially reduce or eliminate our assets, which may have a material adverse effect on the ability of the Issuer to service its indebtedness (including the debt securities) or that would afford holders of such debt securities protection from a material adverse effect resulting from:
(1) a highly leveraged or similar transaction involving the Issuer, or its management, or any affiliate of any of those parties;
(2) a change of control involving the Issuer; or
(3) a reorganization, restructuring, merger or similar transaction involving the Issuer;
Furthermore, subject to the limitations set forth herein under “—Merger, Consolidation or Sale” or as otherwise described in the prospectus supplement relating to the debt securities of any series, the Issuer may, in the future, enter into certain transactions, such as the sale of all or substantially all of the assets of the Issuer or a merger or consolidation involving the Issuer, that would significantly increase the leverage of the Issuer or eliminate or otherwise substantially reduce the assets of the Issuer, which may have a material adverse effect on the ability of the Issuer to service its indebtedness (including the debt securities).
Denominations, Interest, Registration and Transfer
Unless otherwise described in the applicable prospectus supplement, the debt securities of any series will be issuable in denominations of $2,000 and integral multiples of $1,000.
Unless otherwise described in the applicable prospectus supplement and except to the extent the debt securities of any series are issued in book-entry form and held by or on behalf of a depository with arrangements to the contrary, the principal of, and any premium and interest on, the debt securities of any series will be payable at any office or agency applicable to such payments, provided that, at the option of the Issuer, payment of interest may be made by check mailed to the address of the person entitled thereto as it appears in the security register or by wire transfer of funds to that person at an account maintained within the United States.
Any interest not punctually paid or duly provided for on any interest payment date with respect to a debt security will forthwith cease to be payable to the holder of such debt security on the applicable regular record date and may either be paid to the person in whose name such debt security is registered at the close of business on a special record date for the payment of the interest not punctually paid or duly provided for, to be fixed by the trustee, notice whereof shall be given to the holder of such debt security not less than 10 days prior to the special record date, or may be paid at any time in any other lawful manner if such payment is deemed practicable by the trustee, all as more completely described in the indenture.
Subject to certain limitations imposed upon debt securities issued in book-entry form, the debt securities of any series, at the option of the holders thereof, will be exchangeable for other debt securities of the same series and of a like aggregate principal amount and tenor of different authorized denominations upon surrender of those debt securities at any office or agency applicable to such exchanges. In addition, subject to certain limitations imposed upon debt securities issued in book-entry form, the debt securities of any series may be surrendered for registration of transfer or exchange thereof at any office or agency applicable thereto. Every debt security surrendered for registration of transfer or exchange shall be duly endorsed or accompanied by a written instrument of transfer in a form satisfactory to the Issuer. No service charge will be imposed for any registration of transfer or exchange of any debt securities, but the Issuer may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with any registration of transfer or exchange of debt securities other than certain exchanges specified in the indenture that do not involve a transfer. The Issuer may from time to time designate one or more offices or agencies in addition to, or in lieu of the corporate trust office of the trustee, as well as rescind any such designation, where debt securities may be presented or surrendered for payment or for registration of transfer or exchange, except that the Issuer will be required to maintain a an office or agency in each specified place of payment for such debt securities.
 
17

Table of Contents
 
Neither the Issuer nor any trustee shall be required to:
(1) issue, register the transfer of or exchange the debt securities of any series during a period beginning at the opening of business 15 days before any selection of such debt securities to be redeemed and ending at the close of business on the day of mailing of the relevant notice of redemption;
(2) register the transfer of or exchange any debt security, or portion thereof, selected for redemption, except for the unredeemed portion of any debt security being redeemed in part; or
(3) issue, register the transfer of or exchange any debt security which has been surrendered for repayment at the option of the holder of such debt security, except for the portion, if any, of that debt security not to be so repaid.
Merger, Consolidation or Sale
Except as otherwise described in an applicable prospectus supplement, under the terms of an indenture, the Issuer may not, in any transaction or series of related transactions, consolidate or amalgamate with or merge with or into any person or sell, assign, transfer, lease or otherwise convey all or substantially all its assets to any person unless:
(1) either (A) the Issuer shall be the continuing, successor or surviving person, or (B) the successor person (if other than the Issuer) formed by or resulting from such consolidation, amalgamation or merger, or to whom such sale, assignment, transfer, lease or other conveyance is made, (i) shall be a corporation, limited liability company, partnership or other entity organized and existing under the laws of the United States of America, any state thereof or the District of Columbia or any territory of the United States of America and (ii) shall expressly assume the due and punctual performance and observance of every obligation in the indenture and the outstanding debt securities on the part of the Issuer to be performed or observed;
(2) immediately after giving effect to such transaction or series of related transactions, no event of default, and no event which, after notice or lapse of time, or both, would become an event of default, shall have occurred and be continuing; and
(3) the Issuer shall have delivered to the trustee an officers’ certificate and a legal opinion, each stating that such consolidation, amalgamation, merger, sale, assignment, transfer, lease or other conveyance complies with the indenture and that all conditions precedent in the indenture provided for relating to such transaction or series of related transactions have been complied with.
For purposes of the foregoing, any sale, assignment, transfer, lease or other conveyance of all or any of the assets of one or more subsidiaries of the Issuer or another subsidiary, whether directly or as part of a consolidation, amalgamation or merger, which, if such assets were owned by the Issuer would constitute all or substantially all of the assets of the Issuer, shall be deemed to be the conveyance of all or substantially all of the assets of the Issuer to any such person under the indenture.
If the Issuer shall, in any transaction or series of related transactions, consolidate or amalgamate with or merge with or into any person or sell, assign, transfer, lease or otherwise convey all or substantially all its assets to any person, in accordance with the indenture, the successor person formed by or resulting from such consolidation, amalgamation or merger or to whom such sale, assignment, transfer, lease or other conveyance is made, shall succeed to, and be substituted for, and may exercise every right and power of, the Issuer under the indenture, with respect to the outstanding debt securities, with the same effect as if such successor person had been named as the Issuer in the indenture; and thereafter, except in the case of a lease, the predecessor person shall be released from all obligations and covenants under indenture and the outstanding debt securities.
Covenants
The applicable prospectus supplement for the debt securities of any series will describe any important covenants applicable to such debt securities.
 
18

Table of Contents
 
Events of Default, Notice and Waiver
Unless otherwise specified in the applicable prospectus supplement relating to the debt securities of any series, any of the following events are events of default with respect the debt securities of such series:
(1) default in the payment of any interest on any debt security of such series when due and the continuance of such default for 30 days;
(2) default in the payment of the principal of, or any premium on, any debt security of such series when due at maturity or otherwise;
(3) default in deposit of any sinking fund payment, if applicable, for any debt security of such series when due;
(4) default in the performance or observance, or breach, of any covenant or other agreement of the Issuer in the indenture or any debt security of such series (other than one for which the consequences of a default or breach are addressed under another clause described herein under “—Events of Default, Notice and Waiver” or one added to the indenture solely for the benefit of the debt securities of a series other than such series), and the continuance of such default or breach for a period of 60 days after written notice of such default or breach is given to the Issuer by the trustee or to the Issuer and the trustee by the holders of not less than 25% in principal amount of the outstanding debt securities of such series and requiring such payment or other default to be remedied;
(5) certain events of bankruptcy, insolvency or reorganization, or court appointment of a receiver, liquidator or trustee of the Issuer occur;
(6) if the debt securities of such series are entitled to the benefits of any guarantee, such guarantee is not, or is claimed by the applicable guarantor to not be, in full force and effect at any time; and
(7) any other event of default provided in or pursuant to the indenture with respect to the debt securities of such series.
Within 30 days after becoming aware of the occurrence of any event of default under the indenture, or any default that with notice or the lapse of time, or both, would be an event of default under the indenture, the Issuer is required to notify the trustee in writing setting forth the details of such event of default or default, as the case may be, its status and the action that the Issuer is taking or proposes to take, if any, in respect thereof.
If an event of default other than an event of default under clause (5) above with respect to debt securities of any series occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of such series may declare the principal of, and any premium due on, or such lesser amount as may be provided for in the terms of the debt securities of such series, and any accrued and unpaid interest on, all of the debt securities of such series to be due and payable immediately by written notice thereof to the Issuer and to the trustee if such notice is given by the holders of such debt securities. However, at any time after a declaration of acceleration with respect to the debt securities of such series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of such series, by written notice to the Issuer, may rescind and annul such declaration and its consequences if:
(1) the Issuer shall have deposited with the trustee all overdue payments of the principal of, and any premium and interest on, the debt securities of such series other than solely as a result of such declaration of acceleration, plus certain fees, expenses, disbursements and advances of the trustee and its agents and counsel, and
(2) all events of default, other than the non-payment of the principal thereof and any premium and interest thereon with respect to debt securities of such series which shall have become due and payable solely as a result of such declaration of acceleration, shall have been cured or waived under the indenture.
No such rescission shall affect any subsequent default or impair any right consequent thereon.
If an event of default under clause (5) above with respect to the debt securities of any series occurs, then the principal of, and any premium due on, or such lesser amount as may be provided for in the terms of the debt
 
19

Table of Contents
 
securities of such series, and any accrued and unpaid interest on, the debt securities of such series shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of debt securities of such series.
The holders of a majority in principal amount of the outstanding debt securities of any series may waive any continuing default with respect to such debt securities and its consequences, except a default in the payment of the principal of, or any premium or interest on, any debt security of such series, or in respect of a covenant or provision contained in the indenture that cannot be modified or amended without the consent of the holder of each outstanding debt security affected thereby. Upon any such waiver, such default shall cease to exist, and any event of default arising therefrom shall be deemed to have been cured but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.
Within 60 days after the trustee has actual knowledge of the occurrence of any default or event of default with respect to the debt securities of any series unless such default or event of default has been cured or waived under the indenture, the trustee is required to give written notice to the holders of the debt securities of such series within 90 days of a default under the indenture. The trustee shall not be charged with actual knowledge of any default or event of default unless (i) a responsible officer of the trustee shall have actual knowledge of such default or event of default or (ii) the trustee shall have received written notice of such default or event of default by the Issuer or by the holders of not less than 25% in principal amount of the outstanding debt securities of such series, and such notice is received by the trustee its corporate trust office, and such notice references the debt securities of such series. Subject to provisions in the indenture relating to its duties in case of a default with respect to the debt securities of any series, the trustee is under no obligation to exercise any of its rights or powers vested in it under the indenture at the request or direction of any holders of the debt securities of such series, unless those holders shall have offered to the trustee security or indemnity reasonably satisfactory to it.
No holder of any debt security of any series may institute any proceeding, judicial or otherwise, with respect to the indenture or such debt security, or for the appointment of a receiver or trustee, or for any remedy thereunder, unless: (1) such holder has previously given written notice to the trustee of a continuing event of default with respect to the debt securities of such series; (2) the holders of not less than 25% in principal amount of the outstanding debt securities of such series have made written request to the trustee to institute a proceeding in respect of such event of default in its own name as trustee; (3) such holder(s) have offered to the trustee indemnity or security reasonably satisfactory to it against the losses, damages, costs, expenses and liabilities to be incurred in compliance with such request; (4) the trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and (5) no direction inconsistent with such written request has been given to the trustee during such 60-day period by the holders of a majority in principal amount of the outstanding debt securities of such series; it being understood and intended that no one or more of such holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of the indenture or any debt security to affect, disturb or prejudice the rights of any other such holders or holders of the debt securities of any other series, or to obtain or to seek to obtain priority or preference over any other holders or to enforce any right under the indenture, except as otherwise provided in the indenture and for the equal and ratable benefit of all such holders.
The holders of a majority in principal amount of the outstanding debt securities of any series shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred upon the trustee with respect to the debt securities of such series. However, the trustee may refuse to follow any direction which (1) is in conflict with any law or the indenture or the debt securities of any series, (2) is inconsistent with other action the trustee deems to be proper or (3) may be unduly prejudicial to the rights of other holders of debt securities of such series (or any other series) not joining therein.
Notwithstanding the foregoing, the holder of any debt security may institute suit for the enforcement of payment of the principal of, and any premium and interest on, such debt security at the respective due dates thereof.
Within 120 days after the close of each fiscal year, the Issuer must deliver to the trustee a written statement of two specified officers as to whether, to their knowledge, (i) there is a default by the Issuer in the performance and
 
20

Table of Contents
 
observance of the indenture or the outstanding debt securities (without regard to notice requirements and/or periods of grace) or (ii) there is a default which, with notice or the lapse of time or both, would become an event of default or an event of default has occurred or is continuing, and specifying all such defaults and events of default and the nature and status thereof; provided that any default that results solely from the taking of an action that would have been permitted but for the continuation of a previous default will be deemed to be cured if such previous default is cured prior to becoming an event of default.
Modification
Modifications and amendments of the indenture and any debt securities may be made by the Issuer and the trustee only with the consent of the holders of a majority in principal amount of the outstanding debt securities of each series affected by such modification or amendment (voting as separate classes); provided, however, that no such modification or amendment may, without the consent of the holder of each outstanding debt security affected thereby:
(1) change the stated maturity of the principal of, or any premium or interest on, such debt security, or reduce the principal amount of, or any premium on, or the rate or rates (or change the calculation of the rate or rates) of interest on, such debt security;
(2) reduce (or change the manner of calculating) the amount payable upon the redemption or repayment of any such debt security, or change any date on, or period during which, any such debt security is subject to optional or mandatory redemption or repayment or otherwise alter the provisions relating thereto in a manner adverse to the interests of the holder or beneficial owners thereof;
(3) reduce the amount of principal of an original issue discount security that would be due and payable upon acceleration of the maturity thereof or would be provable in bankruptcy;
(4) change the place of payment where, or the currency in which the payment of principal of, or any premium or interest on, such debt security is payable;
(5) impair the right to institute suit for the enforcement of any payment due with respect to such debt security;
(6) reduce the percentage in principal amount of the outstanding debt securities of any series the consent of whose holder is necessary to modify or amend the indenture or to waive compliance with certain provisions thereof or certain defaults and consequences thereunder provided for in the indenture;
(7) modify any of the foregoing provisions or any of the provisions relating to the waiver of certain covenants thereof or certain defaults and consequences thereunder, except to increase the percentage in principal amount of the outstanding debt securities of any series the consent of whose holders is necessary therefor or to provide that certain other provisions of the indenture may not be modified or waived without the consent of the holder of each outstanding debt security affected thereby; or
(8) reduce the quorum or voting requirements set forth in the indenture.
The holders of a majority in principal amount of outstanding debt securities of any series have the right, to the extent specified in the applicable prospectus supplement, to waive prospective compliance by the Issuer with one or more covenants applicable to the debt securities of such series either in specific circumstances or generally.
Modifications and amendments of the indenture and any debt securities may be made by the Issuer and the trustee without the consent of any holder of debt securities of any series for any of the following purposes:
(1) to evidence the succession of another person to the Issuer and the assumption by any such succession of the covenants of the Issuer in the indenture and any debt securities;
(2) to add to the covenants of the Issuer for the benefit of the holders of the debt securities of all or any series or to surrender any right or power conferred upon the Issuer with respect to the debt securities of all or any series;
 
21

Table of Contents
 
(3) to add events of default for the benefit of the holders of the debt securities of all or any series;
(4) to change or eliminate any payment restrictions in respect of any debt securities or to permit or to facilitate the issuance of debt securities in global or uncertificated form, provided that any such action shall not adversely affect the interests of any holder or beneficial owner of any outstanding debt security of any series;
(5) to amend or supplement any provision in the indenture or any debt securities, provided that any such action does not apply to any outstanding debt securities of any series which are entitled to the benefit of, or subject to, such provision;
(6) to secure the debt securities or to secure or add guarantees for the benefit of the debt securities of all or any series;
(7) to establish the form or terms of debt securities of any series, including the provisions and procedures, if applicable, for the conversion and/or exchange of those debt securities into any securities or other property;
(8) to evidence and provide for the acceptance of appointment by a successor trustee with respect to the debt securities of one or more series and to add to or change provisions necessary to provide for or facilitate the administration of the trusts under the indenture by more than one trustee;
(9) to cure any mistake or ambiguity, or to correct or supplement any defect or inconsistency in the indenture or any debt securities or to make any other provisions with respect to matters or questions arising thereunder, or to make any change necessary to comply with the Trust Indenture Act, provided that any such action shall not adversely affect the interests of any holder or beneficial owner of any outstanding debt security of any series;
(10) to supplement any of the provisions of the indenture to the extent necessary to permit or facilitate the legal defeasance, covenant defeasance and/or satisfaction and discharge of the debt securities of any series, provided that any such action shall not adversely affect the interests of any holder or beneficial owner of any outstanding debt security of any series;
(11) to conform the terms of the indenture or the debt securities of any series to the description thereof contained in any prospectus, prospectus supplement, term sheet or other offering document relating to the offer and sale of such debt securities; or
(12) to make any change necessary to comply with the applicable rules or procedures of the depository, if any, or any rules or regulations of any securities exchange or automated quotation system on which any of the debt securities may be listed or traded, in each case which shall not adversely affect the interests of any holder or beneficial owner of any outstanding debt security of any series.
The indenture may provide that in determining whether the holders of the requisite principal amount of outstanding debt securities of any series have given any request, demand, authorization, direction, notice, consent or waiver thereunder or whether a quorum is present at a meeting of holders of debt securities:
(1) the principal amount of an original issue discount security that shall be deemed to be outstanding shall be the amount of the principal thereof that would be due and payable prior to its stated maturity at the date of that determination;
(2) the principal amount of a debt security denominated in a foreign currency that shall be deemed outstanding shall be the U.S. Dollar equivalent, determined at original issuance, of the principal amount thereof (or, in the case of an original issue discount security, the U.S. Dollar equivalent at original issuance of such debt security of the amount determined as provided in clause (1) above);
(3) the principal amount of an indexed security that shall be deemed outstanding shall be the principal amount of such indexed security at original issuance, unless otherwise provided with respect to the terms of such indexed security; and
(4) debt securities owned by the Issuer or any other obligor in respect of the debt securities or any affiliate of the Issuer or such other obligor shall be disregarded.
 
22

Table of Contents
 
The indenture may contain provisions for convening meetings of the holders of debt securities of any series to make, give or take any request, demand, authorization, direction, notice, consent, waiver or other action contemplated under the indenture. A meeting for any such purpose may be called at any time by the trustee and also, upon request, by the Issuer or the holders of at least 10% in principal amount of the outstanding debt securities of such series upon written notice.
The holders of a majority in principal amount of the outstanding debt securities of any series shall constitute a quorum for any meeting of holders of the debt securities of such series; provided, however, that if any action is to be taken with respect to a matter that the indenture expressly provides may only be given by the consent of the holders of a supermajority in principal amount of the outstanding debt securities of any series, then the holders of the specified supermajority in principal amount of the debt securities of such series shall constitute a quorum.
Except for any consent that must be given by the holder of each debt security affected by modifications and amendments of the indenture, any resolution presented to the holders of the debt securities of any series at a meeting at which a quorum is present may be adopted by the affirmative vote of the holders of a majority in principal amount of the outstanding debt securities of such series; provided, however, that, except as referred to above, any resolution with respect to any request, demand, authorization, direction, notice, consent, waiver or other action that may be made, given or taken by the holders of a specified percentage, which is greater or less than a majority, in principal amount of the outstanding debt securities of a series may be adopted at a meeting at which a quorum is present by the affirmative vote of the holders of such specified percentage in principal amount of the outstanding debt securities of such series. Any resolution passed or decision taken at any meeting of holders of debt securities of any series duly held in accordance with the indenture will be binding on all holders of debt securities of such series.
Discharge, Legal Defeasance and Covenant Defeasance
The indenture shall cease to exist with respect to the debt securities of any series when (1) all debt securities of such series other than (A) debt securities of such series which have been discharged, lost or stolen and which have been replaced or paid and (B) debt securities of such series for whose payment money has been deposited in trust or segregated and held in trust and thereafter repaid to the Issuer or discharged from such trust have been delivered to the trustee for cancellation or (2) all debt securities of such series not already delivered to the trustee for cancellation (A) have become due and payable, (B) will become due and payable within one year, or (C) if redeemable at the option of the Issuer, are to be called for redemption within one year under arrangements reasonably satisfactory to the trustee for the giving of notice of redemption by the trustee, and the Issuer has irrevocably deposited with the trustee, in trust for holders of such debt securities, money in the currency in which such debt securities is payable in an amount sufficient to pay the entire indebtedness represented by such debt securities, including the principal of, and any premium and interest on, such debt securities to the date of such deposit (if such debt securities have become due and payable) or to the maturity or earlier redemption of such debt securities.
Unless the terms of the debt securities of any series provide otherwise, the Issuer may elect:
(1) to defease and be discharged from any and all of its obligations with respect to such debt securities, except for (A) the rights of holders of such debt securities to receive payments of principal thereof and any premium and interest thereon then due ratably from the trust funds, (B) the obligations to register the transfer or exchange of such debt securities, and to replace temporary or mutilated, destroyed, lost or stolen debt securities, (C) the obligations to maintain an office or agency in respect of such debt securities, and (D) any rights of holders of such debt securities to repurchase or repay at their option, and the obligations of the Issuer to repurchase or repay such debt securities upon exercise of such option or otherwise (“legal defeasance”); or
(2) if so provided in the terms of the debt securities of such series, to be released from its obligations with respect to any covenant so specified in the applicable prospectus supplement, and any omission to comply with those obligations shall not constitute a default or an event of default with respect to such debt securities (“covenant defeasance”).
 
23

Table of Contents
 
The following shall be the conditions to the legal defeasance or covenant defeasance with respect to any outstanding debt securities of or within a series:
(a) The Issuer shall irrevocably have deposited with the trustee, in trust for the holders of such debt securities, (1) an amount of money in the currency in which such debt securities are then specified as payable at their stated maturities or, if such legal defeasance or covenant defeasance is to be effected in compliance with subsection (f) below, on the relevant redemption date, as the case may be, (2) Government Obligations (as defined below) applicable to such debt securities (determined on the basis of the currency in which such debt securities are then specified as payable at their stated maturities or, if such legal defeasance or covenant defeasance is to be effected in compliance with subsection (f) below, on the relevant redemption date, as the case may be) which through the scheduled payment of principal and interest in respect thereof in accordance with their terms will provide money in an amount, or (3) a combination thereof, in any case, in an amount, sufficient, without consideration of any reinvestment of such principal and interest, in the written opinion of a nationally recognized firm of independent public accountants or a nationally recognized investment bank delivered to the trustee, to pay and discharge, and which shall be applied by the trustee to pay and discharge, (y) the principal of, and any premium and interest on, such debt securities at the stated maturities of such principal and interest, and (z) any mandatory sinking fund payments or analogous payments applicable to such outstanding debt securities on the day on which such payments are due and payable in accordance with the terms of the indenture and such debt securities.
(b) Such legal defeasance or covenant defeasance shall not result in a breach or violation of, or constitute a default under, the indenture or any other material agreement or instrument to which the Issuer is a party or by which it is bound.
(c) No event of default or event which, with notice or lapse of time or both, would become an event of default with respect to such debt securities shall have occurred and be continuing on the date of such deposit, and, solely in the case of legal defeasance, no event of default with respect to such debt securities under clause (5) under “—Events of Default, Notice and Waiver” above or event which with notice or lapse of time or both would become an event of default with respect to such debt securities under clause (5) under “—Events of Default, Notice and Waiver” above shall have occurred and be continuing at any time during the period ending on and including the 91st day after the date of such deposit.
(d) In the case of legal defeasance, the Issuer shall have delivered to the trustee an opinion of counsel stating that (x) the Issuer has received from, or there has been published by, the U.S. Internal Revenue Service a ruling, or (y) since the date of the indenture, there has been a change in applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion of counsel shall confirm that, the holders and beneficial owners of such outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such legal defeasance had not occurred; or, in the case of covenant defeasance, the Issuer shall have delivered to the trustee an opinion of counsel to the effect that the holders and beneficial owners of such debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such covenant defeasance had not occurred.
(e) The Issuer shall have delivered to the trustee an officers’ certificate and an opinion of counsel, each stating that all conditions precedent to the legal defeasance or covenant defeasance, as the case may be, under the indenture have been compiled with.
(f) If the monies or Government Obligations or combination thereof, as the case may be, deposited under subsection (a) above are sufficient to pay the principal of, and any premium and interest on, such debt securities on a particular redemption date, the Issuer shall have given the trustee irrevocable instructions to redeem such debt securities on such date and to provide notice of such redemption to holders thereof as provided in or pursuant to the indenture.
 
24

Table of Contents
 
“Government Obligations” means securities which are:
(1) direct obligations of the United States of America or such other government which issued the foreign currency in which the principal of, or any premium and interest on, the debt securities of a particular series is payable, in each case where the payment is supported by the full faith and credit of the United States of America or such other government, as applicable; or
(2) obligations of a person controlled or supervised by, and acting as an agency or instrumentality of, the United States of America or such other government which issued the foreign currency in which the principal of, or any premium and interest on, the debt securities of such series is payable, in each case where the timely payment thereunder is unconditionally guaranteed as a full faith and credit obligation by the United States of America or such other government, as applicable,
which, in either case, are not callable or redeemable at the option of the issuer thereof, and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such Government Obligation or a specific payment of interest on, or principal of, or other amount with respect to, any such Government Obligation held by the custodian for the account of the holder of a depository receipt, provided that (except as required by law) the custodian is not authorized to make any deduction from the amount payable to the holder of the depository receipt from any amount received by the custodian in respect of such Government Obligation or the specific payment of interest on, principal of, or other amount with respect to, such Government Obligation evidenced by the depository receipt.
In the event we effect covenant defeasance with respect to the debt securities of any series and such debt securities are declared due and payable because of the occurrence of any event of default other than the event of default described in clause (4) under “—Events of Default, Notice and Waiver” above in respect of any covenant specified in the applicable prospectus supplement as to which such debt securities are subject to covenant defeasance, the funds in trust with the trustee may not be sufficient to pay amounts due in respect of such debt securities at the time of the acceleration resulting from such event of default since those funds were intended to be sufficient to pay amounts due in respect of such debt securities only at the time of their stated maturities. However, the Issuer would remain liable to make payment of those amounts due at the time of acceleration.
Conversion or Exchange Rights
The terms and conditions, if any, upon which the debt securities of a series may be convertible into, and/or exchangeable for, securities or other property will be set forth in the applicable prospectus supplement relating to such debt securities. Those terms will include details on the securities or other property into or for which such debt securities are convertible and/or exchangeable, the conversion and/or exchange price (or manner of calculation thereof), the conversion and/or exchange date(s) or period(s) (or manner of determining the same), the provisions as to whether, and upon what terms, any conversion and/or exchange will be mandatory or at the option of the Issuer or the option of the holders of such debt securities, the provisions requiring an adjustment to the conversion and/or exchange price and the provisions affecting conversion and/or exchange in the event of the redemption of such debt securities.
Trustee
We intend to name the indenture trustee for each series of debt securities in the applicable prospectus supplement.
Global Securities
The debt securities of a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf of, the depositary identified in the applicable prospectus supplement relating to such debt securities. Global securities may be issued in either registered or bearer form and in either temporary or permanent form. The applicable prospectus supplement will describe the terms of the depositary arrangement with respect to such debt securities.
 
25

Table of Contents​
 
SELLING STOCKHOLDERS
Pursuant to the Registration Rights Agreement, certain of our stockholders are entitled to rights with respect to the registration of their shares under the Securities Act. These registration rights include the right to demand that we file with the SEC a registration statement on Form S-3 covering the registration of their registrable securities for resale, subject to certain conditions. In accordance with this obligation, this prospectus covers the possible resale or other disposition from time to time by the Selling Stockholders identified in the table below and their respective permitted transferees, pledgees, distributees, donees or other successors-in-interest of up to an aggregate of 120,453,642 shares of our common stock, which represent the Selling Stockholder Shares. The Selling Stockholders may from time to time offer and sell, transfer or otherwise dispose of any or all of the Selling Stockholder Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement.
We are registering the Selling Stockholder Shares to permit the Selling Stockholders and their respective transferees, pledgees, distributees, donees or other successors-in-interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under “Plan of Distribution” herein.
For more information about our relationships with the Selling Stockholders and their affiliates, see “Certain Relationships and Related Party Transactions” in our definitive proxy statement on Schedule 14A, filed with the SEC on April 8, 2025, which is incorporated by reference herein. Except as otherwise disclosed herein or in a filing incorporated by reference herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us.
The table below sets forth the number of shares of our common stock beneficially owned by the Selling Stockholders, the number of shares of our common stock that may be offered under this prospectus and the number of shares of our common stock beneficially owned by the Selling Stockholders assuming all of the shares covered hereby are sold. Percentage ownership of our common stock is based on 143,106,447 shares of our common stock issued and outstanding as of August 4, 2025. We have determined beneficial ownership in accordance with the rules of the SEC. Thus, it represents sole or shared voting or investment power with respect to our securities, and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed all of the shares of our common stock subject to time-vesting restricted stock units (“RSUs”) that will vest within 60 days of August 4, 2025 to be outstanding and beneficially owned by the person or entity holding the RSUs for the purpose of computing the percentage ownership of that person or entity but have not treated them as outstanding for the purpose of computing the percentage ownership of any other person or entity.
The Selling Stockholders may sell, transfer or otherwise dispose of some, all or none of the shares of our common stock that may be offered hereunder. We do not know when the shares of our common stock will be sold, transferred or otherwise disposed of by the Selling Stockholders, and the Selling Stockholders may offer the shares of our common stock from time to time.
Unless otherwise indicated below, the address of each Selling Stockholder listed in the table is c/o Ardent Health, Inc., 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027.
 
26

Table of Contents
 
The information set forth in the table below is based upon information obtained from the Selling Stockholders and upon information known to us.
​ ​ ​
Shares of
Common Stock
Beneficially Owned
​ ​
Shares of
Common
Stock
That May be
Sold
Hereunder
​ ​
Shares of Common Stock
Beneficially
Owned After Sale of All
Common Stock That
May be Sold Hereunder(1)
​
Name of Selling Stockholder
​ ​
Shares
​ ​
Percentage
​ ​
Shares
​ ​
Percentage
​
EGI-AM(2)
​ ​ ​ ​ 77,246,499 ​ ​ ​ ​ ​ 54.0% ​ ​ ​ ​ ​ 77,246,499 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Pure Health(3)
​ ​ ​ ​ 30,262,664 ​ ​ ​ ​ ​ 21.1% ​ ​ ​ ​ ​ 30,262,664 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Ventas(4)
​ ​ ​ ​ 9,342,501 ​ ​ ​ ​ ​ 6.5% ​ ​ ​ ​ ​ 9,342,501 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
David Vandewater(5)
​ ​ ​ ​ 1,767,959 ​ ​ ​ ​ ​ 1.2% ​ ​ ​ ​ ​ 1,767,959 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Stephen C. Petrovich(6)
​ ​ ​ ​ 1,051,089 ​ ​ ​ ​ ​ * ​ ​ ​ ​ ​ 1,043,423 ​ ​ ​ ​ ​ 7,666 ​ ​ ​ ​ ​ * ​ ​
Neil Hemphill(7)
​ ​ ​ ​ 790,596 ​ ​ ​ ​ ​ * ​ ​ ​ ​ ​ 790,596 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
* Less than 1%
(1) Assumes that each of the Selling Stockholders sells all of their Selling Stockholder Shares covered by this prospectus and does not acquire beneficial ownership of any additional shares of our common stock.
(2) Each of EGI-AM Investor, L.L.C., the manager of EGI-AM, and Chai Trust Company, LLC, the managing member of EGI-AM Investor, L.L.C., shares voting and dispositive power over the 77,246,499 shares held by EGI-AM. The address of these entities is Two North Riverside Plaza, Suite 600, Chicago, Illinois 60606.
(3) Each of (i) Pure Health, (ii) Pure Health Holding PJSC, a public joint stock company whose shares are listed on the Abu Dhabi Securities Exchange and the ultimate parent of Pure Health, (iii) Pure Health Capital LLC, the sole shareholder of Pure Health, and (iv) Pure Health Medical Supplies LLC, the controlling member of Pure Health Capital LLC, share voting and dispositive power over the 30,262,664 shares held by Pure Health. The address for Pure Health is 2462 RsCo-work01, 24th Floor, Al Sila Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates (“UAE”). The address for Pure Health Holding PJSC is Al Dar Real Estate Investment L.L.C. Building, RBW11,0, Al Raha Beach, 2 Al Raha Street, Abu Dhabi, UAE. The address for Pure Health Medical Supplies LLC is Office Number 3401 Vision Tower, Al Khaleej Al Tejar Street 1, Business Bay, Dubai, UAE, PO. Box: 283572. The address for Pure Health Capital LLC is 2, Al Rahah Street, Al Rahah, Abu Dhabi, 23035, UAE.
(4) Ventas is the sole stockholder of VTR AMS, Inc., the sole and managing member of ALH Holdings, LLC, and has sole voting and dispositive power over the 9,342,501 shares held by ALH Holdings, LLC. The address for Ventas is 300 N. LaSalle Street, Suite 1600, Chicago, Illinois 60654.
(5) Includes (i) 836,833 shares of common stock held by PEDS Strategic Investments, LLC, of which Mr. Vandewater is the managing member, (ii) 465,563 shares of common stock held by The David T. Vandewater 2015 GST-Exempt Family Trust Dated 12/2/15 (the “DTV Trust”), of which Stephen T. Braun is the trustee, and (iii) 465,563 shares of common stock held by The Phyllis B. Vandewater 2015 GST-Exempt Family Trust Dated 12/2/2015 (the “PBV Trust”), of which Mr. Vandewater is the trustee. The address for PEDS Strategic Investments, LLC, the DTV Trust and the PBV Trust is 30 Burton Hills Blvd., #355, Nashville, Tennessee 37215.
(6) Includes (i) 186,225 shares of common stock held by the Emilie K. Petrovich GST-2016 Exempt Family Trust, of which Mr. Petrovich is the trustee and Mr. Petrovich’s children are beneficiaries, and (ii) 186,225 shares of common stock held by the Stephen C. Petrovich GST-2016 Exempt Family Trust, of which Mr. Petrovich’s spouse is the trustee and Mr. Petrovich’s children are beneficiaries. Mr. Petrovich disclaims beneficial ownership of these securities, except to the extent of Mr. Petrovich’s pecuniary interests therein, if any. Mr. Petrovich’s beneficial ownership also includes 3,233 RSUs scheduled to vest on September 25, 2025. Mr. Petrovich is the Executive Vice President and General Counsel of the Company.
(7) Includes (i) 640,596 shares of common stock held by the NHND Trust, of which Mr. Hemphill and his spouse are co-trustees and joint beneficiaries, (ii) 50,000 shares of common stock held by the Michael Tyler Hardin 2024 Trust (the “MTH Trust”), of which Mr. Hemphill is the settlor, his spouse is the trustee and his son Michael is the sole beneficiary, (iii) 50,000 shares of common stock held by the Robert Michael Hemphill 2024 Trust (the “RMH Trust”), of which Mr. Hemphill is the settlor, his spouse is the trustee and his son Robert is the sole beneficiary, and (iv) 50,000 shares of common stock held by The Hemphill Family Foundation, a Texas non-profit corporation, of which Mr. Hemphill serves as President and Chairman of the Board. Mr. Hemphill disclaims beneficial ownership of the securities held by the MTH Trust, RMH Trust and The Hemphill Family Foundation, except to the extent of Mr. Hemphill’s pecuniary interests therein, if any. The address for the MTH Trust, the RMH Trust and The Hemphill Family Foundation is 7739 Fair Oaks Parkway, Fair Oaks Ranch, Texas 78015.
 
27

Table of Contents​
 
PLAN OF DISTRIBUTION
Our Plan of Distribution
We may sell the securities covered by this prospectus in any one or more of the following ways from time to time:
•
to or through one or more underwriters, brokers or dealers;
​
•
block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
​
•
through agents to investors or the public;
​
•
in short or long transactions;
​
•
through put or call option transactions relating to our common stock;
​
•
directly to agents or other purchasers;
​
•
in “at the market offerings” within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise;
​
•
though a combination of any such methods of sale; or
​
•
through any other method described in the applicable prospectus supplement.
​
In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing securityholders. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement.
We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. We will, in the prospectus supplement relating to such offering, name any agent that could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis.
The distribution of the securities may be effected from time to time in one or more transactions:
•
at a fixed price, or prices, which may be changed from time to time;
​
•
at market prices prevailing at the time of sale;
​
•
at prices related to such prevailing market prices; or
​
•
at negotiated prices.
​
The applicable prospectus supplement will set forth the terms of the offering and the method of distribution and will identify any firms acting as underwriters, dealers or agents in connection with the offering, including:
•
the terms of the offering;
​
•
the names of any underwriters, dealers or agents;
​
•
the name(s) of any managing underwriter(s);
​
•
the purchase price of the securities and the proceeds to us from the sale;
​
•
any over-allotment options under which the underwriters may purchase additional securities from us;
​
•
any underwriting discounts, concessions, commissions or agency fees and other items constituting compensation to underwriters, dealers or agents;
​
•
any delayed delivery arrangements;
​
•
any public offering price;
​
 
28

Table of Contents
 
•
any discounts or concessions allowed or re-allowed or paid by underwriters or dealers to other dealers; or
​
•
any securities exchange or market on which the securities offered in the prospectus supplement may be listed.
​
If we use underwriters for a sale of securities, the underwriters will acquire the securities for their own account for resale to the public, either on a firm commitment basis or a best efforts basis. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Underwriters may offer the securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. If underwriters are used in the sale of securities hereunder, an underwriting agreement will be executed with the underwriters at the time an agreement for sale is reached. Unless we inform you otherwise in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions. We may change from time to time any public offering price and any discounts or concessions the underwriters allow or pay to dealers.
During and after an offering through underwriters, the underwriters may purchase and sell the securities in the open market. These transactions may include overallotment and stabilizing transactions and purchases to cover syndicate short positions created in connection with the offering. The underwriters may also impose a penalty bid, which means that selling concessions allowed to syndicate members or other broker-dealers for the offered securities sold for their account may be reclaimed by the syndicate if the offered securities are repurchased by the syndicate in stabilizing or covering transactions. These activities may stabilize, maintain or otherwise affect the market price of the offered securities, which may be higher than the price that might otherwise prevail in the open market. If commenced, the underwriters may discontinue these activities at any time.
Under Rule 15c6-1 under the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an underwriter in a firm commitment underwritten offering. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.
Some or all of the securities that we offer through this prospectus may be new issues of securities with no established trading market. Any underwriters to whom we sell our securities for public offering and sale may make a market in those securities, but they will not be obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity of, or continued trading markets for, any securities that we offer.
If dealers are used for the sale of securities, we, or an underwriter, will sell the securities to them as principals. The dealers may then resell those securities to the public at varying prices determined by the dealers at the time of resale. We will include in the applicable prospectus supplement the names of the dealers and the terms of the transaction.
We may also sell the securities through agents designated from time to time. In the applicable prospectus supplement, we will name any agent involved in the offer or sale of the offered securities, and we will describe any commissions payable to the agent. Unless we inform you otherwise in the applicable prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.
We may sell the securities directly in transactions not involving underwriters, dealers or agents.
We may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities. We will describe the terms of any such sales in the applicable prospectus supplement.
 
29

Table of Contents
 
Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the applicable securities laws and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the applicable securities laws. We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation. We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities, including liabilities under the applicable securities laws.
Underwriters, dealers and agents may engage in transactions with or perform services for us in the ordinary course of their businesses for which they may receive customary fees and reimbursement of expenses.
We may use underwriters with whom we have a material relationship. We will describe the nature of such relationship in the applicable prospectus supplement.
Under the securities laws of some states, the securities offered by this prospectus may be sold in those states only through registered or licensed brokers or dealers.
We may enter into hedging transactions with broker-dealers and the broker-dealers may engage in short sales of the securities in the course of hedging the positions they assume with us, including, without limitation, in connection with distributions of the securities by those broker-dealers. We may enter into option or other transactions with broker-dealers that involve the delivery of the securities offered hereby to the broker-dealers, who may then resell or otherwise transfer those securities. We may also loan or pledge the securities offered hereby to a broker-dealer and the broker-dealer may sell the securities offered hereby so loaned or upon a default may sell or otherwise transfer the pledged securities offered hereby.
Selling Stockholders’ Plan of Distribution
The Selling Stockholders or their permitted transferees, pledgees, distributees, donees or other successors-in-interest may, from time to time after the date of this prospectus, sell, transfer or otherwise dispose of up to an aggregate of 120,453,642 shares of our common stock held by them, which represent the Selling Stockholder Shares. We are registering the Selling Stockholder Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of the Selling Stockholder Shares in accordance with the Registration Rights Agreement. We will not receive any of the proceeds from the sale by the Selling Stockholders of the Selling Stockholder Shares. We will, or will procure to, bear all fees and expenses incident to our obligation to register the Selling Stockholder Shares.
The Selling Stockholders may sell all or a portion of the Selling Stockholder Shares beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the Selling Stockholder Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent’s commissions. The Selling Stockholder Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, through distributions in kind for no consideration, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions that involve cross trades or block transactions. The Selling Stockholders may use any one or more of the following methods when selling Selling Stockholder Shares:
•
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
​
•
block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
​
•
to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
​
 
30

Table of Contents
 
•
an exchange distribution in accordance with the rules of the applicable exchange;
​
•
privately negotiated transactions;
​
•
settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
​
•
an agreement with broker-dealers to sell a specified number of such shares at a stipulated price per share;
​
•
through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise;
​
•
a combination of any such methods of sale; and
​
•
any other method permitted pursuant to applicable law.
​
The Selling Stockholders also may resell all or a portion of the Selling Stockholder Shares in open market transactions in reliance upon Rule 144 under the Securities Act, as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions.
Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling Selling Stockholder Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Selling Stockholder Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as to be set forth in a supplement to this prospectus, in the case of an agency transaction, will not be in excess of a customary brokerage commission in compliance with Financial Industry Regulatory Authority (“FINRA”) Rule 2121; or, in the case of a principal transaction, a markup or markdown in compliance with FINRA IM-2121.01.
In connection with sales of the Selling Stockholder Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Selling Stockholder Shares in the course of hedging in positions they assume. The Selling Stockholders may also sell Selling Stockholder Shares short and if such short sale shall take place after the date that the registration statement, of which this prospectus forms a part, has been declared effective by the SEC, the Selling Stockholders may deliver Selling Stockholder Shares covered by this prospectus to close out short positions and to return borrowed Selling Stockholder Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Selling Stockholder Shares to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Selling Stockholder Shares to cover short sales of our common stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC.
The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Selling Stockholder Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Selling Stockholder Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of Selling Stockholders to include the permitted transferees, pledgees, distributees, donees or other successors-in-interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Selling Stockholder Shares in other circumstances in which case the permitted transferees, pledgees, distributees, donees or other successors-in-interest will be the selling beneficial owners for purposes of this prospectus.
 
31

Table of Contents
 
The Selling Stockholders and any broker-dealer or agents participating in the distribution of the Selling Stockholder Shares may be deemed to be “underwriters” within the meaning of Section 2(a)(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent, and any profit on the resale of the shares purchased by them, may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are “underwriters” within the meaning of Section 2(a)(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act.
At the time a particular offering of the Selling Stockholder Shares is made, a prospectus supplement, if required, will be distributed, which will set forth the name of the Selling Stockholder, the aggregate amount of shares being offered by the Selling Stockholder and the terms of the offering, including, to the extent required, (1) the name or names of any underwriters, broker-dealers or agents, (2) any discounts, commissions and other terms constituting compensation from the Selling Stockholder and (3) any discounts, commissions or concessions allowed or re-allowed to be paid to broker-dealers.
Under the securities laws of some U.S. states, the Selling Stockholder Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the Selling Stockholder Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.
There can be no assurance that any Selling Stockholder will sell any or all of the Selling Stockholder Shares registered pursuant to the registration statement, of which this prospectus forms a part.
Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Selling Stockholder Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Selling Stockholder Shares to engage in market-making activities with respect to the Selling Stockholder Shares. All of the foregoing may affect the marketability of the Selling Stockholder Shares and the ability of any person or entity to engage in market-making activities with respect to the Selling Stockholder Shares.
We will pay all expenses of the registration of the Selling Stockholder Shares pursuant to the Registration Rights Agreement, including, without limitation, SEC filing fees, legal expenses incurred by us and all reasonable legal expenses incurred by counsel for the Selling Stockholders; provided, however, that each Selling Stockholder will pay all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Selling Stockholder Shares.
We may be required to indemnify the Selling Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the Registration Rights Agreement, or the Selling Stockholders may be entitled to contribution. We and our directors, officers and control persons may be indemnified by the Selling Stockholders against certain liabilities, including some liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the Registration Rights Agreement, or we or they may be entitled to contribution.
 
32

Table of Contents​​
 
LEGAL MATTERS
The validity of the shares of our common stock, shares of preferred stock and debt securities offered by us pursuant to this prospectus will be passed upon for us by Sidley Austin LLP. The validity of the shares of our common stock offered by the Selling Stockholders pursuant to this prospectus will be passed upon for us by Stephen C. Petrovich, our Executive Vice President and General Counsel. Any underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in any applicable prospectus supplement.
EXPERTS
The consolidated financial statements of Ardent Health, Inc. (formerly Ardent Health Partners, Inc.) appearing in our Annual Report (Form 10-K) for the year ended December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated by reference herein. Such consolidated financial statements are incorporated by reference herein in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
 
33

Table of Contents
​
​
8,000,000 shares
[MISSING IMAGE: lg_ardenthealth-4clr.jpg]
Common stock
​
PRELIMINARY PROSPECTUS SUPPLEMENT
​
J.P. MorganBarclays
​
BofA Securities
​ ​ Citigroup ​ ​
Leerink Partners
​ ​
Mizuho
​
​
RBC Capital Markets
​ ​
Stephens Inc.
​ ​
Truist Securities
​
​ ​ ​ ​
Capital One Securities
​ ​ ​ ​
​
      , 2026
​
​

Keep reading